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1 Introduction 
1.1 Lipid raft 
Lipid rafts organize the plasma membrane into specialized microdomains which act as 
platforms for the conduction of different cell functions including vesicular trafficking and 
signal transduction [1]. Classic lipid rafts are enriched in cholesterol, glycosphingolipid and 
raft markers such as flotillin (Fig. 1.1A-B) [2, 3].  
 
Fig. 1.1 Lipid raft microdomains can be classified by the ultrastructure of the membrane intermediates. 
(A) Clathrin-coated pit as vesicular lipid raft and planar lipid raft, (B) clathrin-coated pit and (C) caveolae 
structures. The electron micrographs shown is own unpublished image from tracheal muscle of Cav-3
-/-
 mice (*) 
or from the COS-1 cell line [4] with permission (**). Cav-1, caveolin-1; Cav-3, caveolin-3. 
1.2 Caveolae  
1.2.1 Structural and functional role  
Caveolae are flask-shaped invaginations of the plasma membrane (50-100 nm in diameter) 
with a high content of cholesterol and glycosphingolipids; they can be viewed as a subset of 
lipid rafts (Fig. 1.2). Caveolae are distinguished from other lipid rafts by the presence of 
caveolins as structural proteins that appear to be responsible for stabilizing the caveolae 
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structure (Fig. 1.1B) [2, 5-7]. There is a remarkable variation in caveolar density in different 
tissues [8]. Each caveolae consists of 140-150 caveolin molecules [9]. Caveolae are anchored 
to the plasma membrane via the cytoskeleton and are abundant in mature smooth muscle cells 
(SMC) [10, 11]. Caveolae concentrate numerous structural proteins, ion channels, G-protein-
coupled receptors (GPCR) and receptor kinases and play a key role in pathways associated 
with cell proliferation, calcium homeostasis, migration, mechanosensing, cholinergic 
signaling via muscarinic receptors (MR) and airway smooth muscle cell (ASM) constriction 
[11-19]. The importance of caveolae is highlighted by links between their dysfunction and 
human diseases including lipodystrophy, muscular dystrophies, cardiac disease, infection, 
osteoporosis and cancer [8, 20, 21].  
 
Fig. 1.2 Caveolae are specialized lipid rafts enriched in cholesterol and sphingolipids, characterised by the 
presence of caveolins. (A) A structural cartoon of a caveola depicting the organisation of caveolins, signaling 
and EHD-2 proteins. (B) Caveolin protein structure showing the amino-terminus, carboxy-terminus and 
scaffolding domain which interact with cholesterol and signaling molecules. (C) Selected area of a caveolae 
structure indicated by the boxed area in (A) that presents the association of the caveolin oligomer, the lipid 
bilayer, glycosphingolipids, phospholipid, cholesterol and signaling molecules. AC, adenylyl cyclase; C, protein 
carboxy-terminus; eNOS, endothelial nitric oxide synthase; GPCR, G-protein coupled receptor; MAPK, 
mitogen-activated protein kinase; N, protein amino-terminus; PKA, protein kinase A; PKC, protein kinase C. 
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1.2.2 Caveolins 
1.2.2.1 Caveolin structure 
Caveolins (Cav-1, -2, and -3) are acylated 22-24 kDa proteins embedded in the cytosolic 
leaflet of cell membranes with both amino (N-) and carboxyl (C-) termini residing in the 
cytosol (Fig. 1.2) [22, 23]. Cav interact with themselves to oligomerize (∼14-16 Cav 
monomers per oligomer) and can bind to additional proteins via the caveolin scaffolding 
domain (residues 82 to 101 in Cav-1) or carboxyl tail (Fig. 1.2) [3, 24, 25]. Cav-1 and Cav-3  
are essential for caveolae formation and serve as binding partners for receptors and enzymes 
[14]. Some cell types including smooth muscle and cardiomyocytes express all types of 
caveolins [26-28]. Caveolin levels show dramatic differences from tissue to tissue [8].  
1.2.2.2 Cav-1 
Cav-1 is widely expressed in type I pneumocytes, endothelial cells, adipocytes, fibroblasts 
and SMC [14, 29]. Cav-1 and Cav-2 are generally expressed together [14].  
Cav-1 has emerged as a critical regulator of signaling pathways involved in lung fibrosis, 
inflammation, NO production by endothelial nitric oxide synthase (eNOS), microvascular 
permeability, Ca
2+
 entry into endothelial cells, vascular remodeling and angiogenesis [24, 30-
34].  
1.2.2.3 Cav-3 
Cav-3 is expressed highly in striated muscle cells (skeletal and cardiac muscle) and certain 
SMC and is critical for caveolae formation in the same manner as Cav-1 elsewhere [29, 35, 
36]. Cav-3 is 60% homologous to Cav-1 with the major differences occurring in the N-
terminal portion of the protein. Cav-3 expression is detectable at embryonic day 10 in a 
mouse heart, and it has been shown to associate with the developing T-tubule system in 
skeletal myoblasts [37, 38]. Cav-3 expression and caveolae formation are required to generate 
a highly organized/fully mature T-tubule system in vivo [3]. In prior studies, we have shown 
that both Cav-1 and Cav-3 are present and interact in murine ASM [16]. Cav-1/Cav-3 hetero-
oligomeric complexes were also observed in rat and mouse myocytes from mice 
overexpressing Cav-1 [39, 40]. Furthermore, Cav-3 regulates the switch from synthetic to 
contractile phenotype in vascular SMC [41]. 
Cav-3 has been shown to interact with a variety of signaling molecules including Gi2α, Gβγ, 
c-Src, and Src-like kinases in C2C12 cells, suggesting a role for Cav-3 in the transduction 
events mediated by these molecules [29]. Cav-3 has also been reported to directly interact 
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with the neuronal nitric oxide synthase isoform (nNOS) expressed in skeletal muscle and 
causes the inhibition of nNOS enzymatic activity [35, 36]. Cav-3 is a negative regulator of 
p42/44 MAPK, and loss of Cav-3 expression is sufficient to induce cardiomyopathy [24].  
1.2.2.4 Cav deficiency 
Phenotypes of caveolin knockout mice (Cav KO) include metabolic disorders associated with 
adipose tissue abnormalities, airway hyperresponsiveness, urogenital alterations, deregulation 
of the eNOS signaling pathway, pulmonary hypercellularity, cardiac disease, altered 
susceptibility to tumorigenesis and skeletal muscle myopathy [42, 43]. Specific phenotypes 
were described in Cav KO animals reflecting the importance of Cav expression in particular 
tissues. Surprisingly, all transgenic animals were viable and fertile despite a loss of muscle-
caveolae in Cav-3 KO animals or non-muscle-caveolae in the absence of Cav-1 [42].  
Most of the abnormalities observed in Cav-1 KO are localized within the lungs, adipose 
tissue, and vascular compartment [14]. Interestingly, an immunohistochemical analysis of 
endobronchial biopsies of asthmatic patients revealed a remarkable loss of Cav-1 compared to 
the control group [44]. The major vascular, cardiac, and pulmonary phenotypes in Cav-1 KO 
are largely caused by the loss of caveolae in the endothelium of these organs, supporting the 
concept that endothelial Cav-1 can regulate remodeling of cardiac and pulmonary tissues [32]. 
Cav-3 deficiency, in line with its muscle-specific expression, leads to skeletal muscle 
pathology and cardiomyopathy through multiple pathogenic mechanisms in mice [3, 45]. 
Interestingly, skeletal muscle fibers from Cav-3 KO mice show a number of myopathic 
changes, consistent with a mild-to-moderate muscular dystrophy phenotype [46]. Similar to 
Cav-1 KO mice, the p42/44 MAP kinase cascade is hyperactivated in the hearts of Cav-3 KO 
mice and may partly account for cardiac defects [46]. In case of a heart failure, there is an 
extensive remodeling of the T-tubule network and this change may contribute to abnormal 
calcium handling [47]. Furthermore, a mutation in Cav-3 has been found in familial 
hypertrophic cardiomyopathy [48] and the skeletal muscles of patients with limb girdle 
muscular dystrophy [49]. These effects can be due to a dominant-negative effect of the 
mutated Cav-3 and its retention in the Golgi apparatus, disorganization of skeletal muscle T-
tubule network or disruption of distinct cell-signaling pathways.  
The genetic loss of both Cav-1 and Cav-3 results in severe cardiomyopathy and a dramatic 
increase in the left ventricular wall thickness. These effects can be due to the alteration of 
caveolin levels as a negative regulator of proliferation, hypertrophy, or remodeling by 
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modulating signal transduction (such as β-adrenergic signaling, NO, and the MAPK cascade), 
or by structural disarrangement of the T-tubule system or impaired calcium homeostasis [50-
52].  
1.2.3 EHD  
Proteins within the Eps15 homology domain-containing protein family (EHDs) have been 
shown to participate in the remodeling of membranes in the endosomal system [53]. The 
mammalian genome encodes four EHDs, EHD1-4 [53]. EHD-2 oligomers (ATPase) as  ring 
structures are bound and localized to the caveolae neck to stabilize and control the dynamics 
of such invaginations at the cell surface [53, 54]. Intriguingly, EHD-2 is not required for the 
caveolae formation but acts as a negative regulator of endocytosis and its depletion results in 
an increased caveolin mobility and caveolae budding [55, 56]. The expression of EHD-2 is 
also reduced In Cav-1
-/-
 and cavin-1
-/-
 mice, thereby providing direct evidence for its link to 
the caveolar abundance and function [57].  
1.2.4 Cavin  
Over the past few years, a new family of cytoplasmic proteins, termed cavins, has also been 
shown to have the potential to dynamically transmit signals from caveolae to various cellular 
destinations [8]. The cavin family includes cavin-1 to -4 and stabilizes the mature classical 
flask-shaped caveolae (Fig. 1.3) [58]. All cavins share conserved α-helical secondary structure 
elements within two clearly delineated regions called helical region (HR) which are separated 
by three disordered regions as proteolytic and phosphorylation sites (DR) (Fig. 1.3). Cavins 
possess the ability to associate into higher ordered homo- and hetero-oligomers [59]. 
Additionally, all of the cavins through their N-terminal domains can bind phosphatidylserine 
which is abundant on the cytoplasmic face of the plasma membrane, particularly in areas that 
are rich in caveolae [60, 61]. The ratio of cavin-1 to Cav-1 was estimated to be 1 to 4 and is 
independent of other cavins [59]. 
Cavin-1 (synonym: PTRF, polymerase I and transcript release factor) acts as a nuclear protein 
[62]. Cavin-2 (synonym: SDPR, serum deprivation response protein) and cavin-3 (synonym: 
SRBC, srd-related gene product that binds to c-kinase) are identified as protein kinase C 
(PKC) substrates and have been suggested to target PKC to caveolae [63, 64]. Cavin-4 
(synonym: MURC, muscle-restricted coiled-coil protein) is predominantly expressed in 
cardiac and skeletal muscle and links to myogenesis and muscle hypertrophy via the Rho-
associated kinase (ROCK), ERK1 and ERK2 [65-67].  
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The change in the recruitment of cavins to caveolins might change the architecture of 
caveolae and contributes to the disassembly of the entire structure. The high cholesterol 
content of the caveolar domain is also crucial for the Cav-cavin integrity [68, 69] and  
dissociation of Cav-1-cavin-1 flattens the caveolar structure [70]. The fact that cavins show 
tissue-specific expression profiles implies that the cavin proteins could generate differences 
between caveolae in diverse tissues or cell types [57, 58].  
Cavin-1 is required for the formation of caveolae, and the absence of cavin-1 in both cultured 
cells and animal systems causes a loss of caveolae [68, 71]. Early studies showed that cavin-1 
co-localizes with Cav-1 in adipose tissues and cavin-1 over-expression increases the Cav-1 
level and its knockdown reduces the Cav-1 level [71, 72]. Importantly, the tissue distribution 
of cavin-1 is broader than that of Cav-1 and is dominant in both muscle and non-muscle 
tissues [73]. It is not surprising that the phenotypes of cavin-1 KO mice are similar to those of 
Cav-1/Cav-3 double knockouts [49, 71, 74-77]. Indeed, the absence of cavin-1 leads to a 
suppressed protein expression of all three caveolin isoforms [73].  
Cavin-2 has been linked to determining the size or stability of cavin complexes for caveolae 
generation in lung and fat endothelia, as the deletion of cavin-2 actually increases the apparent 
size of cavin complexes and reduces the depth of caveolae in lung endothelium [57]. Cavin-3 
does not appear to be needed for generating endothelial caveolae but has the properties to link 
caveolae to signal transduction pathways [57, 78]. Cavin-4 was shown to be associated with 
muscle biogenesis [66] and its knocking down or over-expression has been shown to impair 
or improve the differentiation of mouse C2C12 myoblasts through decreased or increased 
ERK1/2 activation in the differentiation stages [79]. Cavin-4 expression is perturbed in human 
muscle diseases associated with a Cav-3 dysfunction [21]. 
Most clinical features of cavin mutated patients are then likely to be explained by the 
secondary reduction of a caveolae and/or caveolin deficiency. For example, the missense 
mutations of cavin-1 are associated with deficiency and mislocalization of all three caveolin 
family members [21]. It seems that cavin-1 mutation affects its interaction with Cav-3 and 
reduces the caveolae structures in skeletal muscle biopsies [21]. Both Cav-3 and cavin-4 
mutations have been linked to dysregulation of hypertrophy and hypertrophic signaling 
pathways in cardiac and skeletal muscle [8]. Mutations in human Cav-3 or cavin-1 result in 
human cardiomyopathies such as the long-QT syndrome [20, 80].  
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Fig. 1.3 Caveolin and cavin complex. (A) Cavin structure. (B) Caveolin oligomers embed in the cell membrane 
but do not form caveolae structure. The presence of cavin allows caveolins to form a caveolae structure. Cav, 
caveolin; DR, disordered regions; HR, helical region.  
1.3 Regulation of airway smooth muscle tone 
1.3.1 Structure of the airway tree  
The respiratory system is composed of a tree-like structure of branched tubes that carry air to 
and from the alveoli. This basic design is conserved among vertebrates, but there are 
important differences between mouse and human airways due to the very large differences in 
body size. Transgenic mouse models are very largely used for studying the respiratory 
function, and the trachea, being the largest airway, is equivalent to the diameter of the small 
peripheral airways in the human lung. In mice, cartilage rings are only present in the 
extrapulmonary airways, but cartilage extends for several bronchial generations into the 
human lung. Since the cartilage amount differs along the airway tree, we expected that the SM 
constriction would also differ because of differences in the stiffness of the airway wall. 
Submucosal glands which produce mucins and other factors are restricted to the proximal 
trachea in the mouse but reach deep into the human lung [81]. Striking interspecies 
differences are also found with respect to the cellular composition and receptors in the 
airways [81]. The cellular composition and organization of the mouse trachea is much more 
similar to human small airways, whereas the mouse intrapulmonary airway resembles only the 
most distal portions of the human conducting airways [81]. From this, we conceive that it is 
important to know the agonist-induced airway SM constriction of different parts of the murine 
airways. Here we show that all compartments of the airway (extra- and intrapulmonary) have 
different impact on their response to contractile stimuli such as muscarine and serotonin 
(synonym: 5-HT, 5-Hydroxytryptamine). 
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1.3.2 G-protein-coupled receptors  
GPCR, also known as seven-transmembrane domain receptors, constitute the largest 
superfamily of cell-surface receptors [82]. Several GPCR are not randomly distributed along 
the cell surface but aggregate at caveolae structures [14]. Members of this GPCR family 
include for example 5-HT, β2-adrenergic receptor (β2-AR) and MR [82]. Despite their 
diversity, all GPCR mediate their effects at least in part through coupling to heterotrimeric G- 
proteins comprising α-, β- and γ-subunits. The α-subunit is responsible for GTP and GDP 
binding and GTP hydrolysis, whereas the β- and γ-subunits are associated in a tightly linked 
complex as βγ-dimer. The activated heterotrimer dissociates into an α-subunit and a βγ-dimer, 
both of which have an independent capacity to regulate separate effectors (Tab. 1.1)  [83]. 
Upon agonist activation of receptors, a rapid attenuation of receptor responsiveness occurs 
through feedback mechanisms, which involve phosphorylation of activated GPCR by kinases 
and/or second messenger dependent kinases [82]. 
 
 
 
 
 
 
 
Tab. 1.1 Examples of heterotrimeric G-protein mediated effector functions based on Ref. [83]. Receptors 
are classified by operational, structural and transductional criteria. ↑ Denotes increase, ↓ decrease in cellular 
levels of second messenger. cAMP, cyclic adenosine monophosphate; Ins(1,4,5)P3, inositol-1,4,5-triphosphate; 
DAG, diacylglycerol; GEF, guanine nucleotide exchange factor. 
1.3.2.1 Muscarinic receptors  
Release of acetylcholine (ACh) from parasympathetic nerve fibers causes ASM constriction 
by acting through MR [84]. Five molecularly distinct MR subtypes (M1R-M5R) are known 
(Tab 1.2). We previously identified M2R and M3R as being essential for murine ACh-
induced constriction in bronchial SMC [85]. Within the SM, the highest MR density is in the 
lower trachea, while the upper trachea and bronchi contain significantly less receptors [86, 
87]. In most animal species, there are many more M2R than M3R in the conducting airways. 
Depending on the species, 50 to 80% of the receptors can be M2R [88]. With quantitative 
receptor binding analysis, Ikeda and coworkers reported a significantly higher density of M3R 
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than M2R in human bronchi at different levels [89]. Functional studies indicate that the M3R 
mediates ASM contraction in animals [88] and in humans [90], like in ileal, uterine, and 
bladder SM [91]. The M3R is thought to be coupled primarily via Gαq to phospholipase C 
(PLC) signaling pathways and calcium release mechanisms that support SM contraction. 
Activation of PLC catalyzes the formation of inositol triphosphate and diacylglycerol from 
the membrane phospholipid phosphatidylinositol 4,5-bisphosphate, and coupling of M3R to 
inositol triphosphate has been demonstrated in all studied species including in human 
bronchial SM [92, 93]. The M2R couples to Gαi, thereby inhibiting adenylate cyclase, 
activating nonselective cation channels, and sensitizing the contractile system to calcium [94, 
95]. It seems that M2R do not play a direct role in SM contraction, but inhibit SM relaxation 
through inhibition of adenylyl cyclase (Fig. 1.4) [96, 97]. Furthermore, we previously 
observed a considerable decrease, but not a complete loss of the muscarine-induced 
bronchoconstriction response of M3R
-/-
 mice compared with wild-type mice in precision cut 
lung slice (PCLS). In addition, we used M2R
-/-
 mice to test the contribution of M2R to 
cholinergic constriction of peripheral airways. Interestingly, M2R
-/-
 bronchi showed similar 
muscarine-induced bronchoconstriction compared with wild-type bronchi. Strikingly, 
muscarine-mediated bronchoconstriction was completely abolished in PCLS preparations 
from M2/3R
-/-
 mice [85].  
These results together with earlier findings confirmed that the remaining cholinergic 
bronchoconstriction in M3R
-/-
 mice was mediated by the M2R [16, 85]. Likewise, in the 
murine tracheal SM, M3R and M2R importantly contributed to the muscarinic induced 
contraction [98, 99].  
 MR subtypes are functionally coupled to Cav-isoforms in the heart, urinary bladder SM and 
tracheal SM [18, 100, 101]. We previously observed a decrease in the response to muscarine 
in PCLS after disruption of caveolae with the cholesterol depleting agent, methyl-β-
cyclodextrin (MCD), pointing to an association of either Cav-1 or Cav-3 with airway MR 
[16]. Moreover, disruption of caveolae or knockdown of Cav-1 reduced the MR-mediated 
calcium mobilization in airway SMC [18]. Cav-1 was found to be co-localized with M3R as 
intracellular Ca
2+
 regulatory protein, and the downregulation of Cav-1 expression 
considerably decreased the Ca
2+
 responses to ACh [102]. 
Indeed, the contractile response to the MR agonist carbachol is decreased in the urinary 
bladder of Cav-1
-/-
 mice [100] but the ASM response to methacholine remains unchanged 
[103]. In support of this, own recent data also showed that the airway response to muscarine is 
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unchanged in Cav-1
-/-
 mice [submitted]. M2R are targeted to plasmalemmal caveolae upon 
agonist stimulation in adult rat ventricular myocytes and co-purified with Cav-3 and eNOS 
[104]. In addition, eNOS/Cav-3 interactions hold a key role in the cholinergic modulation of 
cardiac myocyte function [105]. However, functional consequences of the receptor-Cav-3 
interactions in ASM remained poorly defined. We previously showed a direct association 
between M2R and Cav-3 in murine bronchial SMC which suggests that anchoring of M2R to 
caveolae via Cav-3 is important for initiation of M2R-mediated signaling [16].  
 
 
 
 
 
 
 
Tab. 1.2 Characteristics of muscarinic receptors (MR). Receptors are classified by operational, structural and 
transductional criteria. ↑ Denotes increase, ↓ decrease in cellular levels of second messenger. cAMP, cyclic 
adenosine monophosphate; Ins(1,4,5)P3, inositol-1,4,5-triphosphate; DAG, diacylglycerol. 
 
 
 
 
 
 
 
 
Fig. 1.4  Airway smooth muscle contraction.  M3R mediate acetylcholine (ACh)-induced contraction of 
airway smooth muscle (ASM). Prejunctional M2R limit the amount of ACh released from stimulated cholinergic 
axons, thereby limiting the level of bronchoconstriction. In contrast, activation of postjunctional M2R can 
enhance the overall level of bronchoconstriction by opposing ASM relaxation, which might occur through 
activation of β2-adrenergic receptors (β-AR). MR, muscarinic receptor. 
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1.3.2.2 5-HT receptors  
5-HT, a secretory product of mast cells, leads to contraction of airway SMC in situ and in 
vitro acting on a wide variety of G-protein-coupled 5-HT receptor subtypes (Tab. 1.3) [106-
108].  
There is a discrepancy between the effects of 5-HT in vivo and in vitro. Although 5-HT can 
activate human and rat ASM in vitro [109, 110], 5-HT inhalation does not lead to airway 
constriction in vivo [111]. As the 5-HT constrictor pathway involves the direct stimulation of 
bronchial SMC [107], 5-HT inhalation may not reach directly SMC to elicit a constrictor 
effect. It has been shown that increased levels of free 5-HT are present in the plasma of 
symptomatic asthmatic patients compared with levels in asymptomatic patients [112, 113]. 
We showed previously that the MCD treatment completely abolished the bronchoconstrictor 
response to 5-HT, thereby providing evidence for involvement of caveolae-coupled signaling 
pathways [16]. Likewise, this dependency was previously reported in bovine airway and rat 
arterial SMC [114, 115]. Interestingly, the responses to 5-HT were not affected in the absence 
of caveolae in ileal smooth muscle from Cav-1 KO mice [116]. These discrepant findings in 
the response to 5-HT between different tissues highlight the unique regulation of smooth 
muscle function, depending on organ and/or agonist. Generally, 5-HT contraction is mediated 
by i) an increase in calcium influx, and ii) the sustained contraction by calcium sensitization 
process [117, 118] which is regulated by the shift of rhoA, rho kinase and/or PKC from 
caveolar to noncaveolar lipid rafts [119]. A shift of 5-HT2A receptor subtype between 
caveolar and planar lipid raft membrane compartments was observed in cardiomyocytes and 
bovine tracheal SMC [114, 120]. Bhatnagar et al. showed that Cav-1 associates with the 5-
HT2A receptors in HEK-293 and C6 cells and in rat brain synaptic membranes [121]. Mialet-
Perez also demonstrated that 5-HT2A receptors interact with Cav-3 upon 5-HT stimulation, 
and Cav-3 silencing enhances the myocyte hypertrophic response [120]. Moreover, we 
recently showed a complete dependency of the 5-HT response to Cav-1 in murine 
extrapulmonary and a partial dependency in the intrapulmonary airway [submitted].  
The different actions of 5-HT on airways might partly be attributed to the involvement of 
different receptor subtypes and effector systems to which the receptors are linked. The 
receptor subtypes present in airway SMC appear to be species-dependent [122]. In the guinea 
pig, 5-HT2 receptors have been found to play a direct role in airway contraction [123], 
whereas other 5-HT receptor subtypes including 5-HT1 and 5-HT3, 5-HT4 and 5-HT7 have a 
modulatory role [124-126]. Rat tracheal SMC contraction involves the 5-HT2C subtype [127]. 
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Receptors from the 5-HT1 group have also been shown to mediate sheep tracheal contraction, 
whereas 5-HT2 receptors do not seem to be involved in bronchoconstriction [128]. Our RT-
PCR analysis revealed the expression of 5-HT1B, 5-HT2A, 5-HT6 and 5-HT7 receptors as the 
most prevalent subunits in the airways of C57BL/6J mice [submitted]. Ketanserin, as 
pharmacological inhibitor of the 5-HT2A receptors, concentration-dependently abolished 5-
HT-induced constriction in murine PCLS [submitted].  
 
 
 
 
 
 
 
 
 
 
Tab. 1.3 Characteristics of 5-HT receptors. Receptors are classified by operational, structural and 
transductional criteria. ↑ Denotes increase, ↓ decrease in cellular levels of second messenger. cAMP, cyclic 
adenosine monophosphate; Ins(1,4,5)P3, inositol-1,4,5-triphosphate; DAG, diacylglycerol. 
1.3.3 Caveolae/caveolins and smooth muscle contraction 
Caveolae harbor a number of signaling proteins to facilitate GPCR-mediated contraction in 
vascular SM [115, 129], SM from the gastrointestinal tract [130], from the urogenital tract 
[100], and from the myometrium [131].  
Concepts of the role of caveolae in governing muscle contraction include regulation of i) 
calcium entry and homeostasis, and ii) formation of the transverse (T)-tubule system during 
muscle development [12, 13]. Both, Cav-1 and Cav-3 are important for the regulation of 
calcium mediated responses and metabolism [102, 132, 133]. Cav-3 may specifically play a 
role in the formation of the muscular T-tubule system [38, 134].  
Caveolae and Cav-1 appear to be most important in regulating the sensitivity of the airway 
SMC responses to ACh [14, 102, 132]. In human airway SM, Cav-1 was identified as a 
marker of the contractile airway SM phenotype [102, 132].  
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Cav-3 also co-localizes with the nAChR and promoted proper clustering of the nAChR in 
myotubes [135]. The presence of Cav-3 in ASM has been described in the rat tracheal muscle 
[105]. We identified both Cav-1 and Cav-3 in mouse and human ASM on mRNA and protein 
level [16], whereas other groups reported an absence of Cav-3 in isolated human ASM [18, 
102, 136]. 
When myoblasts fuse to form myotubes driving skeletal muscle development, the expression 
of Cav-1 starts to decrease and the expression of the Cav-3, the dominant caveolin of 
differentiated muscle fibers, dramatically increase [38, 137, 138]. In arterial SMC, Cav-3 
regulates the switch between contractile and synthetic phenotypes [41]. 
Vascular SMC co-express either Cav-1 and -2 (in veins) or Cav-1, -2, and -3 (in arteries), 
whereas differentiated cardiac and skeletal muscle cells express only the Cav-3 isoform [139]. 
It seems that, in arteries Cav-1 and -3 are co-expressed or there are different sub-populations 
of SMC which express different caveolin proteins [140]. In addition, Cav-3 may have two 
distinct functions in vascular SMC including regulation of signaling pathways at the plasma 
membrane or regulation of SMC contraction through association with the cytoskeletal 
network [41]. Studies in Cav-1/Cav-3 double knockout mice have indicated that Cav-1 is 
responsible for the formation of the majority of caveolae in bladder SMC while  Cav-3 has an 
as-yet unidentified role in this cell type [75]. These discrepant findings regarding the role of 
Cav-3 in SMC contraction might illustrate important tissue-dependent differences in the role 
of Cav-3 in contraction. 
1.3.4 Hyperreactivity and airway diseases 
Bronchial hyperresponsiveness (BHR) is defined by an excessive contraction of ASM leading 
to bronchial narrowing in response to various inhaled stimuli, and is considered as a hallmark 
in asthma and COPD [141, 142]. In the course of inflammation, a wide range of additional 
contractile stimuli are released acting either directly on bronchial SMC or indirectly through 
neural pathways leading to BHR [84]. In the animal models of hyperresponsiveness, the 
release of ACh from the nerves is considerably increased, while there is no change in the 
sensitivity or expression of M3R on ASM [143]. According to a common concept, M2R are 
dysfunctional and do not control release of ACh in the hyperresponsiveness animal models 
[143]. Moreover, it is suggested that caveolins (Cav-2 and -3) have a functional role in the 
overactivity of the rat urinary bladder SM that occurs in association with hormonal alteration 
[144]. 
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However, the lack of Cav-1 induces ASM hyperresponsiveness in mice and guinea pigs [18, 
43, 145]. Furthermore, Cav-3 directs β2-AR-cAMP signaling to the T-tubular compartment in 
rat cardiomyocytes [146, 147]. cAMP compartmentation is a fundamental strategy which cells 
can orchestrate complex receptor signaling with a single second messenger [147]. The ASM 
is unable to relax when the β-AR is impaired [143]. The ASM hyperresponsiveness may be 
mediated by M2R since activation of these receptors inhibits β-AR-mediated relaxation [143]. 
A cross-talk between M2R and β2-AR and Cav-3 is likely to be present in ASM.  
1.4 Aim of the study 
There is evidence that the mechanisms of ASM constriction involve caveolae and their 
structural protein Cav-3, and dysregulation may be involved in pathogenesis of airway 
hyperreactivity. Thus, the present study aimed to assess the distribution of this caveolar 
structural protein, its interaction with binding partners (cavins), and its functional role in 
cholinergic and serotonergic airway constriction. To this end, immunohistochemical 
localization and co-immunoprecipitation studies were conducted, and Cav-3 deficient mice 
were generated for functional analyses. Given the known regional differences in airway 
responsiveness and underlying mechanisms along the airway tree, murine tracheal segments 
(cranial, middle and caudal) and extra- and intrapulmonary bronchi were separately 
investigated in organ bath experiments (extrapulmonary airways) and by videomorphometry 
in PCLS.   
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2  Materials and methods      
2.1 Mouse genetics and husbandry 
2.1.1 Cav-3 knock-out strategy 
To generate Cav-3 knock-out mice, embryonic stem cells (ESC) were transfected with 
targeting vector and screened for homologous recombination by the PolyGene Company 
(Zurich, Switzerland). Furthermore, they produced the floxed germline within the knock-out 
mouse project 8053. Briefly, the targeting vector expressing neomycin resistance gene (neo
R
) 
flanked by two FRT sites was placed in an upstream of exon-2 which itself was flanked by 
two LoxP sites (Fig. 2.1). ESC were electroporated with the Not I linearized targeting vector 
and the transfected ESC clones were screened to identify the targeted vector by PCR and 
Southern blot analysis using probes external to the targeting vector. Resistant colonies that 
contained neo
R
 were tested for homologous recombination on the 5'-end of the Cav-3 
targeting vector by PCR and Southern blot analysis. These resistant colonies of transfected 
ESC were used to produce a chimeric mouse.  
The resultant chimeric male mouse was mated with C57Bl6/J FLIP deleter females and 
germline transmission of the mutant allele was verified by a PCR analysis of genomic DNA 
from pigmented F1 offspring. Genotyping with 8053 primers flanking the FRT cassette 
indicated one male pup (8052.1007) which shows FLIP mediated deletion of the FRT-flanked 
neo
R
 cassette.  
We used these Cav-3-loxP (floxed) male mice which were produced by the PolyGene 
Company further on to establish a conditional Cav-3 knock-out mouse colony. Moreover, we 
backcrossed the resulting floxed chimeric animals to the C57Bl6/J Cre deleter mouse strain 
from Jackson to obtain Cav-3 knock-out and Cre negative homozygous mice. The loss of the 
genomic locus of interest was confirmed by genotyping, immunohistochemistry and Western 
blot. Genotyping was carried out by a multiplex PCR with primers shown in (Tab. 2.1). 
2.1.2 Animals 
The Cav-3-deficient mice and the corresponding wild-type mice used in all experiments were 
sex and age matched, kept in individually ventilated cages in specific pathogen free (SPF) 
conditions and fed with a standard chow. The animals were held according to the German 
guidelines for care and use of laboratory animals (registration code: 491). They were killed 
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either by inhalation of an overdose of isoflurane (Abbott, Wiesbaden, Germany) or cervical 
dislocation for organ bath recording and videomorphometry experiments, respectively. 
2.2 Genotyping 
2.2.1 DNA extraction 
Tail cuts (0.5-1 cm) were taken and stored at -20°C until use. Total DNA was isolated by 
using the DNeasy blood and tissue kit according to the manufacturer's protocol (Qiagen, 
Hilden, Germany). Briefly, tail cuts were incubated overnight with 180 µl ATL lysis buffer 
and 20 µl proteinase K at 56°C. Then they were mixed vigorously by vortexing, 400 µl AL-
ethanol mixture buffer were added and the solution pipetted to mini column. After two steps 
of washing with AW wash buffer, we placed the column in a clean tube and pipetted 150 µl 
water onto the DNeasy membrane and used a centrifuge to solve the extracted DNA and to 
elute it. 
2.2.2 Polymerase chain reaction (PCR) 
PCR was performed by adding 1 μl cDNA, 0.5 μl of each gene-specific intron-spanning 
primer pair for Cav-3-8053-6f-5r or Cre (20 pM; MWG Biotech, Ebersberg, Germany) 
shown in (Tab. 2.1), 2.5 μl 10X PCR buffer II (100 mM Tris-HCl, 500 mM KCl, pH 8.3), 2 
μl MgCl2 (15 mM), 0.75 μl dNTP (10 mM each), 0.25 μl AmpliTaq Gold polymerase (5 
U/μl; all reagents from Applied Biosystems, Darmstadt, Germany) and 18 μl H2O. The 
cycling conditions were 12 min at 95°C, for 40 cycles: 30 s at 95°C, 30 s at 62°C - 0.5°C per 
cycle, 25 s at 72°C, and a final extension at 72°C for 7 min. The control reaction included the 
absence of DNA template. The PCR products were separated by electrophoresis on a 2% 
TRIS-acetate-EDTA agarose (Biozym GmbH, Wien, Austria) gel.  
The PCR for Cav-3-8053-12f-5r was performed by adding 5 μl diluted cDNA (1/10), 2.5 μl 
of gene-specific intron-spanning primer pair for Cav-3-8053-6f-12r (20 pM; MWG Biotech, 
Ebersberg, Germany) shown in (Tab. 2.1), 2.5 μl 10X  PCR buffer II (100 mM Tris-HCl, 500 
mM KCl, pH 8.3), 2 μl MgCl2 (15 mM), 0.75 μl dNTP (10 mM each), 0.25 μl AmpliTaq 
Gold polymerase (5 U/μl; all reagents from Applied Biosystems, Darmstadt, Germany) and 
12 μl H2O. Cycling conditions were 12 min at 95°C, for 45 cycles: 30 s at 95°C, 30 s at 64°C 
- 0.5°C per cycle, 120 s at 72°C, and a final extension at 72°C for 7 min. Control reaction 
included the absence of DNA template. The PCR products were separated by electrophoresis 
on a 1% TRIS-acetate-EDTA agarose gel. 
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2.3 Human bronchial smooth muscle cells  
Primary human bronchial smooth muscle cells (HBSMC) were commercially purchased from 
Promocell (Heidelberg, Germany, catalog number C-12561) and grown in DMEM (PAA, 
Cölbe, Germany) supplemented with 10% heat inactivated fetal calf serum (FCS) (PAA, 
Cölbe, Germany) and penicillin/streptomycin (Sigma-Aldrich Chemie GmbH, München) in 
humidified 5% CO2-95% air at 37°C incubator. Once the cells were confluent, they were 
trypsinized with 0.25% trypsin (PAA, Cölbe, Germany) and 0.02% EDTA in PBS containing 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4, centrifuged, and the 
precipitate was used for gene expression and Western blot studies. 
2.4 Western blotting 
2.4.1 Protein extraction, electrophoresis, protein transfer and protein detection 
Different murine organs or HBSMC were immediately frozen on dry ice and either processed 
the same day or stored at -80°C. The Cav-3-deficient mice and the corresponding wild-type 
mice were sex and age matched. Samples were homogenized with an homogenizer (Retsch 
MM300, California, USA) in octylglucoside lysis buffer (10 mM Tris-HCl, pH 7.4, 50 mM 
NaCl, 60 mM octylglucoside, and 1% triton X100) (Sigma-Aldrich Chemie GmbH, 
München) supplemented with a concentrated complete mini protease inhibitor cocktail, 
dilution of 1:200 (Roche Diagnostics, Mannheim, Germany) for 10 min. The homogenate 
was cleared by centrifugation at 8000 rpm for 5 min. The protein concentration in each tissue 
was determined using the method by Lowry with a commercially available kit (Bio-Rad, 
Hercules, CA, USA) using Nanodrop 2000 (Thermo Scientific, USA). Then, 50 μg of each 
protein lysate supernatant, mixed with 6 µl of 5X reducing sample buffer (320 mM Tris-HCl 
(pH 6.8), 5% sodium dodecyl sulfate (SDS), 50% glycerol, and 0.25 mg/ml bromophenol 
blue and 1% β-2-mercaptoethanol), boiled for 5 min at 95°C and were loaded onto reducing 
10% or 15% SDS-polyacrylamide gel for electrophoresis. For the caveolin protein with a low 
molecular weight, a 15% SDS-PAGE separating gel, and for cavins and EHD2 proteins, a 
10% SDS-PAGE separating gel was used. For the 15% SDS-PAGE separating gel, 7.5 ml of 
30% acrylamide (Roth, Karlsruhe), 2.8 ml of 2 M Tris-HCl, pH 8.8; 75 µl of 20% SDS 
(Serva, Heidelberg, Germany), 80 µl 10% ammonium persulfate (APS; Merck, Darmstadt, 
Germany), 7.5 µl TEMED (Roth, Karlsruhe, Germany) and 4.62 ml H2O were poured. For 
the 10% SDS-PAGE separating gel, 5 ml of 30% acrylamide, 2.8 ml of 2M Tris-HCl (pH 
8.8), 75 µl of 20% SDS, 80 µl 10% APS, 7.5 µl TEMED and 7.12 ml H2O were mixed. After 
the complete polymerization of the 10% or 15% separating gel, 1 ml 30% acrylamide, 50 µl 
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of 20% SDS, 1.25 ml of 1M TRIS-HCl (pH 6.8), 80 µl 10% APS, 10 µl TEMED and 7.7 ml 
H2O were poured to make the stacking gel. Electrophoresis was performed under reducing 
condition. One liter of the electrophoresis buffer contained 0.025 M TRIS, 0.192 M glycine, 
2.5 ml of 20% SDS and water. Electrophoresis was carried out for 20 min at 75 V followed 
by 100 min at 180 V. Subsequently, the proteins were blotted to polyvinylidine difluoride 
membranes (PVDF; Millipore, Schwalbach, Germany). We kept the PVDF membrane for 30 
s in methanol (Sigma-Aldrich Chemie GmbH, München, Germany), 40 s in transfer buffer 
novex 1X (Thermo Fisher, Darmstadt, Germany) and embedded the membrane between 6 
layers of transfer buffer saturated filter papers without bubbles. From the top, there were 
three layers of filter papers, the electrophoresed gel, the PVDF membrane and another three 
layers of filter papers. The blotting was carried out for 90 min at 90 mA per gel using a semi-
dry blotter (Peqlab GmbH, Erlangen, Germany). Thereafter, the gel was stained for 2 h in 
30% methanol (Sigma-Aldrich Chemie GmbH, München, Germany), 10% acetic acid 
(Merck, Darmstadt, Germany) and 0.2% Coomassie brilliant blue R250 (Sigma-Aldrich 
Chemie GmbH, München, Germany) and destained with a solution containing 40% methanol 
and 10% acetic acid. The blotted PVDF membrane was immersed in TTBS (0.01 M Tris-HCl 
(pH 8.0), 0.2 M NaCl and 0.05% Tween-20) and 10% dried skimmed milk powder (Roth, 
Karlsruhe, Germany) for 3 h to saturate non-specific protein binding sites. Then it was 
incubated overnight with the appropriate antibodies (Tab. 2.2) (diluted in TTBS and 5% milk 
powder; Pierce, Rockford, USA), washed 3 × 10 min with TTBS and incubated with 
secondary horseradish peroxidase-conjugated antibodies (Tab. 2.3) (diluted in TTBS and 
2.5% milk powder; Pierce, Rockford, USA) for 1 h. Immunoreactive bands were visualized 
by the enhanced chemiluminescence kit (Thermo Scientific, USA) with Fusion FX (Vilber 
Lourmat, Australia). The PVDF was blocked in TTBS containing 10% dried skimmed milk 
powder for 5 h. The PVDF membrane was incubated with the primary antibody (β-tubulin or 
succinate dehydrogenase A (SDHA) antibodies as a reference control) overnight. Then, it was 
washed and incubated with secondary horseradish peroxidase-conjugated antibodies. 
Immunoreactive bands were visualized with Fusion FX. Next, the PVDF membrane was 
stained in Ponceau S solution (Sigma-Aldrich Chemie GmbH, München, Germany) for 1 
min. The stained PVDF membrane and the destained gel were scanned. The densitometry 
data were used to calculate the ratio of the target protein to the reference control protein using 
the image J software (Bethesda, Maryland, USA). 
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2.4.2 Statistical analysis 
Nonparametric statistical tests were used. The ratio of densitometric data is presented as box 
plot depicting all quartiles from 0 to 100.  We used the Mann-Whitney U-test to analyze 
differences between Cav-3
+/+ 
and Cav-3
-/-
 mouse strains using SPSS software version 11.5 
(SPSS Software, Munich, Germany). Differences were considered as statistically significant 
when P < 0.05. 
2.5 PCR 
2.5.1 RNA extraction 
Samples from lung, trachea, main bronchus, tracheal muscle, tracheal epithelium and the rest 
of the trachea (epithelium and muscle were removed) from Cav-3
+/+
 and Cav-3
-/-
 mice were 
shock-frozen and stored at -80°C until use. In addition, HBSMC were cultured and after 
confluency, the cells were trypsinized, washed with PBS and centrifuged. There is one more 
step concerning the RNA isolation of epithelial cells. The epithelial cells were abraded from 
the trachea using cotton swabs and purified with a QIA shredder column (Qiagen, Hilden, 
Germany). Total RNA from all tissues was isolated by using the RNeasy method according to 
the manufacturer's protocol (Qiagen, Hilden, Germany). The amount of RNA was determined 
by Nanodrop and diluted to 1 µg/µl with water and stored at -80°C for further processing. 
2.5.2 DNA digestion and reverse transcription  
Contaminating DNA from isolated 8 µl (1 µg/µl) RNA was degraded using 1 µl of DNase I 
(1 U/µl, Invitrogen, Karlsruhe, Germany), 1 µl 10X DNase I reaction buffer (Invitrogen, 
Karlsruhe, Germany) and 8 µl of water for 15 min at 25°C. Then, the enzyme was inactivated 
by the addition of 1 µl ethylene diamine tetra acetic acid (EDTA) (25 mM, pH: 8.0, 
Invitrogen, Karlsruhe, Germany) for 10 min at 65°C followed by an incubation for  5 min on 
ice. For the reverse transcription of mRNA into cDNA, 1 µl oligo DTs (500 µg/µl, Perkin 
Elmer, Ohio, USA), 1 µl dNTP mix (10 mM of each dNTP, Amersham Pharmacia Biotech, 
Freiburg, Germany), 2 µl dithiolthreitol (DTT) (0.1 M, Invitrogen, Karlsruhe, Germany) and 
1 µl Superscript II reverse transcriptase (200 U/µl, Invitrogen, Karlsruhe, Germany) were 
incubated for 50 min at 42°C following 10 min at 72°C to inactivate the Superscript II 
enzyme and then stored until further use at -20°C.  
2.5.3 RT-PCR 
RT-PCR was performed by adding 1 μl cDNA, 0.75 μl of gene-specific intron spanning 
primer sets for murine target genes as shown in (Tab. 2.4) and human target genes as shown 
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in (Tab. 2.5) (20 pM; MWG Biotech, Ebersberg, Germany), 2.5 μl 10X  PCR buffer II (100 
mM Tris-HCl, 500 mM KCl, pH 8.3), 2 μl MgCl2 (15 mM), 0.75 μl dNTP (10 mM each), 
0.25 μl AmpliTaq Gold polymerase (5 U/μl; all reagents from Applied Biosystems, 
Darmstadt, Germany) and 17.75 μl H2O. Cycling conditions were 12 min at 95°C, for 40 
cycles: 30 s at 95°C, 30 s at 59°C, 30 s at 72°C, and a final extension at 72°C for 7 min. The 
PCR products were separated by electrophoresis on a 2% TRIS-acetate-EDTA agarose gel.  
2.5.4 Control reactions 
As a control for sample contamination of with genomic DNA, we performed PCR reaction 
with water instead of cDNA. Additionally, control reactions without adding reverse 
transcriptase enzyme were carried out. Beta-actin primers were used to check the efficiency 
of RNA isolation and cDNA synthesis. 
2.5.5 Gel electrophoresis 
PCR products were separated by electrophoresis in a 2% TRIS-acetate EDTA agarose gel 
containing 20 g/l agarose (Biozym GmbH, Wien, Austria), 482 g/l TRIS (USB, Cleveland, 
USA), 104.2 ml/l glacial acetic acid (Merck, Darmstadt, Germany), 200 ml/l of 0.5 M EDTA 
(Invitrogen, Karlsruhe, Germany) which were solved in 1 l H2O, pH 8.0 with the addition of 
10 µl/l ethidium bromide (1%; Roth GmbH, Karlsruhe, Germany). Twenty-five µl of the 
PCR products were mixed with 5 µl loading buffer (0.1 g Orange G dye (Sigma-Aldrich 
Chemie GmbH, München, Germany), 5.88 ml of 87% glycerol (Sigma-Aldrich Chemie 
GmbH, München, Germany), 250 µl Tris-HCl buffer (pH 8.0), 1 ml EDTA solution (pH 8.0; 
Sigma-Aldrich Chemie GmbH, München, Germany), and mixed in 10 ml H2O and applied in 
the gel. The PCR products were run through a horizontal electrophoresis in a Horizon 11-14 
(Gibco, Karlsruhe, Germany). A 100 bp DNA ladder (Invitrogen, Karlsruhe, Germany) was 
run as marker (6.5 µl). The electrophoresis was carried out at a voltage of 150 V over 45 min. 
The PCR fragments were separated on the gel and were detected by UV illumination using a 
spectrophotometer (Ultrospec 2100 Pro, Biochrom, Cambridge, UK). 
2.5.6 DNA purification and sequencing 
The bands obtained with primers for cavin-1-4 were determined from agarose gel under UV 
light, cut out and transferred to a 2 ml reaction buffer. DNA extraction from the gel was 
carried out using the Gel Extraction Kit (Qiagen, Hilden, Germany) according to the 
instructions of the manufacturer. The absorbance of DNA content was determined by the 
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Nanodrop. Specificities of the amplified gel-extracted PCR products were verified by 
sequencing (MWG Biotech, Ebersberg, Germany). 
2.5.7 Real-time PCR 
Total RNA from lung, trachea, main bronchus, tracheal muscle, tracheal epithelium and the 
rest of the trachea (epithelium and muscle were removed) were isolated from Cav-3
+/+
 and 
Cav-3
-/-
 mice using the RNeasy method as explained before. The Cav-3-deficient mice and 
the corresponding wild-type mice were sex and age matched. Contaminating DNA was 
degraded using 1 unit of DNase I and reverse transcription was carried out as described 
above. Real-time PCR was performed in an iCycler (Bio-Rad, Munich, Germany) using 
QuantiTect SYBR Green PCR Kit (Bio-Rad, Munich, Germany). Characterization of gene- 
specific intron spanning primer sets for cavin-1, cavin-2, cavin-3, cavin-4, Cav-1, EHD2 and 
β-actin is given in (Tab. 2.4) The PCR conditions included initial denaturation in one cycle of 
10 min at 95°C followed by 40 cycles of 30 s at 95°C, 30 s at 60°C, and 30 s at 72°C.  
2.5.8 Calculation of relative expression 
All analyses were done in triplicate and the mean cycle thresholds (CT) for all target genes 
were calculated. The ΔCT of all target genes compared with β-actin was calculated as 
follows: 
ΔCT target gene= CT target gene – CT β-actin  
Control reactions included the absence of DNA template and the absence of reverse 
transcriptase enzyme. The PCR products were separated by electrophoresis on a 2% Tris-
acetate-EDTA agarose gel. 
2.5.9 Statistical analysis 
Nonparametric statistical tests were used. ΔCT values are presented as box plot. Differences 
between Cav-3
+/+ 
and Cav-3
-/-
 groups was analyzed with the Mann-Whitney U-test using 
SPSS software. Differences were considered as statistically significant when P < 0.05. 
2.6 Immunohistochemistry 
2.6.1 Transtracheal filling with OCT compound for immunohistochemistry 
The thorax of the mouse was opened and a plastic cannula (1.1 mm diameter; Braun, 
Melsungen, Germany) was inserted into the trachea. After placing the cannula and fixing it, 
the lungs were filled with approximately 2 ml of OCT compound (Sakura, Zoeterwoude, 
Netherlands) diluted with an equal amount of 0.1 M phosphate buffer (pH 7.4). Then, all 
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thoracic viscera (heart, lungs, trachea, esophagus and thoracic aorta) were removed, frozen on 
filter paper in melting isopentane, transferred to liquid nitrogen, and finally stored at -80°C.  
2.6.2 Paraffin embedding 
Lung biopsies from COPD patients and donors (n=4) were provided by the institute of 
pathology and cytology, Wetzlar (Prof. Ludger Fink). Bronchial samples were fixed in 10% 
formalin according to the standard method and they were embedded in paraffin. The study 
was approved by the local ethical committee (Ref. No. 100/07). 
2.6.3 Indirect immunofluorescence on cryosections 
The tissues to be examined were cut on a cryostat (Microm HM 560, Microm International 
GmbH, Walldorf, Germany) at a thickness of 10 µm and placed on super frost plus slides 
(Menzel-glasses, Braunschweig, Germany). The sections were fixed either for 10 min in 
acetone precooled at -20°C or for 20 min in 4% PFA at room temperature. In case of using 
PFA as fixative, we washed the slides for 2 × 10 min in PBS and 1 × 10 min in distilled 
water. All sections were dried for one h at room temperature. The blocking of nonspecific 
protein binding sites was carried out for one h with one of the following blocking solutions: 
acetone-treated sections with 50% heat inactivated normal horse serum (NHS; 
DakoCytomation, Glostrup, Denmark) in PBS, and for PFA-treated sections 10% heat-
inactivated NHS, 0.5% Tween-20, 0.1% BSA in PBS, pH 7.4. The primary antibodies (Tab. 
2.6) were solved in PBS with addition of 0.01% NaN3 and 0.05 M NaCl (PBS + NaN3 + S) in 
the working dilution and incubated overnight at room temperature. The primary antibodies 
were applied either singly or in combination for double-labeling immunofluorescence. 
Primary antibody combinations were as follows: rabbit anti-Cav-1/mouse anti-α-SMA; rabbit 
anti-cavin-1/mouse anti-α-SMA; rabbit anti-cavin-4/mouse anti-α-SMA; goat anti-Cav-3/ 
mouse anti-α-SMA.  After 3 × 10 min washing with PBS, the corresponding secondary 
antibody was applied in PBS + NaN3 + S for one h. After washing 3 × 10 min with PBS, the 
sections were put for a further 10 min in 4% PFA in 0.1 M phosphate buffer (pH 7.4) to 
conserve the interaction between the primary and the secondary antibodies. Following the 
washing step, the slides were cover-slipped with carbonate buffered glycerol (pH 8.6) and 
stored at a dark place at 4°C.  
2.6.4 Indirect immunofluorescence on paraffin sections 
The paraffin embedded human lung tissues were cut by a microtome (Tetra Santander, Jung, 
Heidelberg, Germany) at a thickness of 8 µm and collected on super frost plus slides. 
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Sections were dried overnight in an incubator (Heraeus, Hanau, Germany) at 37°C, so the 
tissues could adhere better on the slides. Sections were stored at room temperature until use. 
Before incubation with the primary antibody, the sections were deparaffinised (2 × 5 min in 
xylene, absolute, 96%, 80%, 70% and 50% ethanol, respectively, for 5 min). Then the slides 
were placed in a cuvette filled with PBS containing 10% citric acid, pH 6 (Merck, Darmstadt, 
Germany). We floated the cuvette containing the slides in a water bath with 700 ml water and 
put them in a microwave oven for 8 min (800 W). When we saw the first bubble in the bath, 
we continued this process for another 5 min. After this procedure, we put the bath containing 
the slides for about 15 min to cool. We proceeded on by 3 × 5 min washing steps with PBS. 
Next, we incubated the slides with 10% NHS, 0.5% Tween-20, 0.1% BSA in PBS, pH 7.4 for 
1 h before applying the appropriate primary antibody (Tab. 2.6). These antibodies were 
applied either singly or in combination for double-labeling immunofluorescence. Primary 
antibody combinations were as follows: rabbit anti-Cav-1/mouse anti-α-SMA; rabbit anti-
cavin-1/mouse anti-α-SMA; rabbit anti-cavin-4/mouse anti-α-SMA. After 3 × 10 min 
washing with PBS, the corresponding secondary antibody (Tab. 2.7) was applied for 1 h. 
After washing 3 × 10 min with PBS, the sections were put for a further 10 min in 4% PFA 
and they were cover-slipped with carbonate buffered glycerol and stored at 4°C.  
2.6.5 Controls for immunohistochemical studies 
Cryosections of Cav-3 deficient mice were used for confirming the specificity of Cav-3 
antibody labeling. To determine the specificity of the secondary antibody, the primary 
antibody was omitted and incubation with only PBS + NaN3 + S on the sections was applied. 
A monoclonal antibody, isotype IgG2, raised against neuro-filament-68 (Nf-68) was used as 
irrelevant antibody isotype control for the monoclonal anti Cav-3 antibody on sections from 
paraffin embedded specimens. 
2.7 Co-Immunoprecipitation  
2.7.1 Protein extraction and co-immunoprecipitation 
Trachea and lung samples from both Cav-3
+/+
 and Cav-3
-/-
 mice and HBSMC were 
homogenized with a homogenizer in octylglucoside lysis buffer supplemented with 1X  
concentrated protease inhibitor cocktail for 10 min. Skeletal muscle or heart tissue from Cav-
3
+/+
 mice were used as positive control. The homogenate was cleared by centrifugation as 
described in chapter 2.4 Western blotting. Total tissue homogenate (2 mg) for each reaction 
was incubated with 1 µg of experimental antibody (Tab. 2.8) in 150 µl PBS + Tween-20 
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(0.02%) at 4°C and rotated overnight. Then, we added 50 µl dynabeads coated with protein 
G (Life Technologies GmbH, Darmstadt, Germany) to each immunoprecipitation (IP) tube 
and rotated them for 4 h at 4°C. Next, we removed the supernatant and froze the samples for 
further analysis. The dynabeads-antibody-protein complex was washed three times with 200 
µl PBS + Tween-20. Then, we added 100 µl PBS + Tween-20 to the dynabeads-antibody-
protein complex and transferred it to a fresh Eppendorf tube. 
2.7.2 Elution of the proteins from the beads and detection with Western blotting 
We put the fresh Eppendorf tube with dynabeads-antibody-protein complex on a magnetic 
base and removed the PBS. Then, we added 60 μl reducing sample buffer and left it for 5 min 
to boil at 95 °C, followed by gel electrophoresis on a 12% separating gel including 6 ml of 
30% acrylamide, 2.8 ml of 2 M Tris-HCl, pH 8.8, 75 µl of 20% SDS, 80 µl 10% ammonium 
persulfate, 7.5 µl TEMED, 6.12 ml H2O for caveolins and 10% separating gel including 5 ml 
of 30% acrylamide, 2.8 ml of 2 M Tris-HCl pH 8.8, 75 µl of 20% SDS, 80 µl 10% APS, 7.5 
µl TEMED and 7.12 ml H2O for cavins, and electrophoresed the samples in 150 V for 90 
min. Western blot analysis was carried out as explained above. The primary and secondary 
antibodies for Western blot are listed in (Tab. 2.2 and 2.3), respectively. For cavins, we 
loaded 30 µl and for caveolins 20 µl from the sample diluted in 60 μl reducing sample buffer. 
Protein-protein interaction provided by co-immunoprecipitation (CO-IP) is schematically 
diagramed in (Fig. 2.2).  
2.8 Videomorphometry 
2.8.1 Intrapulmonary bronchi 
Precision cut lung slices (PCLS) were prepared using a slightly modified version of the 
protocol described by Martin et al. [148] and reported in detail earlier [16, 85]. Briefly, the 
airways were filled via the cannulated trachea with low melting point agarose (Sigma, 
Taufkirchen, Germany). The lungs and the heart were dissected in HEPES-Ringer containing 
110 mM NaCl, 2.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM HEPES and 11 mM 
glucose. The dissected lung was cooled in cold HEPES 
, and PCLS were cut with a vibratome (VT1000S, Leica, Bensheim, Germany) at a thickness 
of 200 μm from the left lobe of the lung and incubated in minimal essential medium (MEM, 
GIBCO, Karlsruhe, Germany) at 37°C for 2-4 h to remove the agarose. 
Experiments were performed in a HEPES-Ringer buffer in a lung slice superfusion chamber 
(Hugo Sachs Elektronik, March, Germany) mounted on an inverted microscope. Images of 
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the bronchi were recorded with a CCD camera and analyzed with Optimas 6.5 software 
(Stemmer Imaging, Puchheim, Germany) (Fig. 2.3). 
Only those bronchi which responded to a test stimulus of 60 mM KCl with a reduction of 
luminal area of at least 20% were included in the final data analysis. Muscarine and 5-HT 
were purchased from Sigma (Taufkirchen, Germany). Muscarine and 5-HT were dissolved in 
water and diluted in HEPES to the desired experimental concentration immediately before 
use. The volume of the chamber was 1500 µl. All analyses were done and the EC50 in 
response to muscarine and 5-HT were calculated. EC50 of muscarine and 5-HT represent the 
concentration of a compound where 50% of their maximal effects were observed. 
2.8.2 Studying the effect of cumulative concentrations of muscarine and 5-HT on bronchial 
diameter 
PCLS from Cav-3
+/+
 and Cav-3
-/-
 mice were first washed for 5 min to reach an equilibrium, 
then KCl (60 mM) was applied for 5 min as a reference control. The luminal bronchial area 
was measured in 1 min intervals. At least 20% response to KCl compared to baseline was the 
inclusion criterion for the experiments. We washed the slices with HEPES for 20 min to 
remove KCl and to reach the baseline level. Next, muscarine (10
-8
-10
-4
 M) or 5-HT (10
-7
-10
-3
 
M) were administrated at cumulative concentrations (Fig. 2.4A, 4B), each concentration for 
10 min. After administration of the highest concentration we continued washing for 10 min to 
reach the baseline again and applied KCl (60 mM) as a viability control for another 5 min.  
2.8.3 Studying the effect of different application schedules of increasing 5-HT concentrations 
on bronchial diameter 
To test for a desensitizing effect of 5-HT during cumulative application, we additionally used 
three different schedules of 5-HT application (Fig. 2.4C, D). PCLS from Cav-3
+/+
 and Cav-3
-
/-
 mice were first washed for 5 min to reach an equilibrium, then KCl (60 mM) was applied 
for 5 min as a reference control. The luminal bronchial area was measured in 1 min intervals. 
We washed the slices with HEPES for 20 min to remove KCl and to reach the baseline level. 
In the first schedule, we sequentially applied 5-HT at 10
-6
 M, 10
-5
 M and 10
-4
 M as the 
highest concentration. In the second schedule, we applied 5-HT directly at 10
-4
 M and 10
-3
 M.  
2.8.4 Statistical analysis 
Data of videomorphometric experiments are presented as means ± SEM of 4 to 12 bronchi 
obtained from 4 to 6 animals. Because it is principally impossible to test for a normal 
(Gaussian) distribution at such numbers, nonparametric statistical tests were used. 
Differences of minimum luminal area between Cav-3
+/+
 and Cav-3
-/- 
were analyzed with the 
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Kruskal-Wallis test and, in case P < 0.05, followed by Mann-Whitney U-test using SPSS 
software. Differences were considered as statistically significant when P ≤ 0.05. EC50 values 
of agonist responses were estimated using nonlinear regression sigmoidal curve analysis 
using Microsoft Excel. We used the Mann-Whitney U-test to analyze differences between 
Cav-3
+/+ 
and Cav-3
-/-
 mice strains. 
2.9 Organ bath experiment 
2.9.1 Force recording  
The thorax was opened and the submandibular gland was removed. Tracheal rings (4 
cartilages per ring) were isolated from the cranial, middle and caudal parts of the trachea and 
the left main bronchus was dissected. Isometric contraction was measured in isolated rings 
that were mounted between two stainless steel clips in vertical 15 ml organ baths of a 
computerized isolated organ bath system (AD Instruments GmbH, Heidelberg, Germany). 
Baths were filled with MEM and penicillin-streptomycin maintained at 37°C and bubbled 
with a 95% O2/5% CO2 gas mixture. The upper stainless clip was connected to an isometric 
force transducer (Power Lab 8.30; AD Instruments GmbH, Heidelberg, Germany). Tissues 
were equilibrated against a passive load of 0.5 g for all rings (Fig. 2.5). 
At the beginning of each experiment, KCl (60 mM) was administered to each of the rings to 
elicit a reference control. The force response was measured in 1 min intervals. Rings were 
then washed with fresh MEM to eliminate the KCl response. Then a 
cumulative concentration administration of muscarine (10
-9
- 5 × 10
-4
 M) and 5-HT (10
-8
- 10
-4
 
M) was performed (Fig. 2.6). Changes in tension were recorded as a force in 1 min intervals 
and evaluated by software (Lab Chart 7, AD Instruments GmbH, Heidelberg, Germany). All 
analyses were done and the EC50 in response to muscarine and 5-HT were calculated. EC50 
of muscarine and 5-HT represent the concentration of a compound where 50% of their 
maximal effects were observed. The airway reactivity of the response to muscarine or 5-HT 
was calculated as follows: 
Reactivity [muscarine] = Max force [muscarine] / Max force [KCl] or 
Reactivity [5-HT] = Max force [5-HT] / Max force [KCl]. 
2.9.2 Statistical analysis 
Data are presented as means ± SEM of four to seven animals. Differences of maximal force 
response and reactivity between Cav-3
+/+ 
and Cav-3
-/-
 groups and between Cav-3
+/+ 
or Cav-3
-/-
 
tracheal parts and main bronchi were analyzed with the Kruskal-Wallis test. In case P < 0.05, 
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differences between 2 groups were analyzed by Mann-Whitney U-test using SPSS software. 
Differences were considered as statistically significant when P ≤ 0.05. EC50 values of 
agonist responses were estimated using nonlinear regression sigmoidal curve analysis using 
Microsoft Excel. We used the Mann-Whitney U-test to analyze differences between Cav-3
+/+ 
and Cav-3
-/-
 groups and between Cav-3
+/+ 
or Cav-3
-/-
 mice strains. 
 
 
Gene 
 
Primer 
Product 
length (bp)  
Cav-3-loxP 
Product 
length (bp)  
Cav-3
+/+
 
Product 
length (bp)  
Cav-3
-/-
 
 
Cav-3-8053-6F-5R 
 
 
Cav-3-8053-12F-5R 
 
 
Cre 
 
 
 
fwd ttatgcgcaccatcagtc 
rev  cctaggtgtgctcatttg 
 
fwd aaggaggcaatctgggctac 
rev  cctaggtgtgctcatttg 
 
fwd gacaccaccagcaacacact 
rev tccttgaagagcaggacgtg 
 
 
368 
 
 
2000 
 
 
390 
 
323 
 
 
1700 
 
 
390 
 
- 
 
 
497 
 
 
390 
 
Tab.  2.1 Oligonucleotide primers for Cav-3 genotyping. 
 
 
 
Antigen 
 
Host species Dilution Catalog number/Clone Source 
 
Cav-1 (N-20) 
Cav-3 (N-18) 
cavin-1  
cavin-4  
EHD2 
SDHA 
β-tubulin IV 
 
Rabbit (p)  
Goat (p) 
Rabbit (p) 
Goat (p) 
Goat (p) 
Rabbit (p) 
Mouse (m) 
 
 
1:400 
1:300 
1:200 
1:100 
1:500 
1:500 
1:400 
 
 
Sc-894 
Sc-7665 
Ab48824 
Sc-163021 
Ab23935 
Clone 11a 
Mu178-UC/Clone ONS1A6 
 
Santa Cruz, USA 
Santa Cruz, USA 
Abcam, UK 
Santa Cruz, USA 
Abcam, UK 
Own laboratory 
Biogenex, USA 
 
Tab.  2.2 Primary antibodies used for Western blots. P = polyclonal, m = monoclonal antibody. N 
denominates the N-terminus of the protein with 16, 18 and 20 amino acid residues, respectively. 
 
 
 
 
Tab. 2.3 Secondary antibodies used for Western blots. 
 
Antigen Host 
species 
Conjugate Dilution Catalog number Source 
 
Mouse IgG 
Rabbit IgG 
Goat IgG 
 
 
Goat 
Goat 
Rabbit 
 
Peroxidase 
Peroxidase 
Peroxidase 
 
1:10000 
1:10000 
1:5000 
 
M32307 
31460 
61-1620 
 
Thermo Fisher, Germany  
Thermo Scientific, USA 
Thermo Fisher, Germany 
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Gene 
 
Genebank accession No. 
 
Primer 
 
Product length (bp) 
 
cavin-1 
 
 
cavin-2 
 
 
cavin-3 
 
 
cavin-4 
 
 
EHD2 
 
 
β-actin 
 
 
Cav-1 
 
 
Cav-3 
 
NM008986.2 
 
 
NM138741.1 
 
 
NM028444.1 
 
 
NM026509.3 
 
 
NM153068.3 
 
 
NM007393.3 
 
 
NM001243064.1 
 
 
NM007617.3 
 
 
fw dgagcaacaccgtgagcaagt  
rev ctccgactctttcagcgact  
 
fwd tggaacagcgtcagatcaac  
rev ctggctccttcacaaacaca 
 
fwd gacaccaccagcaacacact  
rev tccttgaagagcaggacgtg 
 
fwd gcaacaggttcgtgtaacca  
rev tgctctttgcctgacttcct  
 
fwd tggagagcatcagcatcatc 
 rev gtgggcatcaaagagcaaga 
 
fwd gtgggaatgggtcagaagg  
rev ggcatacagggacagcaca 
 
fwd gcacaccaaggagattgacc  
rev agatgagtgccattgggatg 
 
fwd aggacattcactgcaaggag  
rev gtacttggagacggtgaacg 
 
220 
 
 
290 
 
 
172 
 
 
251 
 
 
140 
 
 
299 
 
 
212 
 
 
167 
 
              
 
Tab.  2.4 Oligonucleotide primers for PCR analysis of murine samples. 
 
 
 
 
Gene 
 
 
Genebank accession No. 
 
Primer 
 
Product length (bp) 
cavin-1 
 
 
cavin-2 
 
 
cavin-3 
 
 
cavin-4 
 
 
EHD2 
 
 
Cav-1 
 
 
Cav-3 
 
NM012232.5 
 
 
NM004657.5 
 
 
NM145040.2 
 
 
NM001018116.2 
 
 
NM014601.3 
 
 
NM001172897.1 
 
 
NM001234.4 
 
fwd gagcaatacggtgagcaagc 
rev ggcagcttcacttcatcctg 
 
fwd ggtcaaagagcgcatggata 
rev ggtttcctccagggatttgt 
 
fwd gacaccaccagcaacacctt 
rev gacttcaccctcctccttga 
 
fwd gctttcacagtcgcatagca 
rev aacaacagacagggatgtcg 
 
fwd atcctcaaactgcccgtcat 
rev gcgagtgaaacttggtgaag 
 
fwd tctctacaccgttcccatcc 
rev caaagagggcagacagcaag 
 
fwd cgtgtggaaggtgagctaca 
rev tgcggatgcagagtgagtag 
 
180 
 
 
208 
 
 
186 
 
 
223 
 
 
127 
 
 
287 
 
 
212 
 
 
Tab. 2.5 Oligonucleotide primers for PCR analysis of human samples. 
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Tab.  2.6 Primary antibodies used for immunohistochemistry.  p = polyclonal, m = monoclonal antibody. N 
denominates the N-terminus of the protein with 18 and 20 amino acid residues, respectively. 
 
 
 
 
Tab.  2.7 Secondary antibodies used for immunohistochemistry. 
 
 
 
 
Tab.  2.8 Antibodies used for precipitation in Co-IP. p = polyclonal, m = monoclonal antibody. N 
denominates the N-terminus of the protein with 18 and 20 amino acid residues, respectively. 
 
 
 
 
 
 
 
Antigen Host species Dilution Catalog number/Clone Source 
 
Cav-1 (N-20) 
Cav-3 
Cav-3 (N-18) 
Cav-1+Cav-3 
cavin-1 
cavin-4  
α-SMA  
Nf-68 
 
Rabbit (p) 
Mouse (m) 
Goat (p) 
Rabbit (p) 
Rabbit (p) 
Rabbit (p) 
Mouse (m) 
Mouse (m) 
 
1:400 
1:300 
1:300 
1:300 
1:200 
1:100 
1:1000 
1:300 
 
Sc-894 
610421/clone 26 
Sc-7665 
63941 
Ab48824 
BP5646a 
F3777/clone 1A4 
N5139/clone Nr4 
 
Santa Cruz, USA 
BD Bioccience, Germany 
Santa Cruz, USA 
BD Bioscience, Germany 
Abcam, UK 
Abgent, USA 
Sigma, Germany 
Sigma, Germany 
Antigen Host species Conjugate Dilution Catalog number Source 
 
Mouse IgG 
Rabbit IgG 
Goat IgG 
 
 
Donkey 
Donkey 
Donkey 
 
 
Cy3 
Cy3 
Cy3  
 
 
1:1000 
1:2000 
1:800 
 
715-165-150 
AP182C 
705-165-003 
 
Dianova, Germany 
Chemicon, USA 
Dianova, Germany 
 
Antigen Host species Concentration Catalog number Source 
 
cavin-1 
Cav-1 (N-20) 
Cav-3 (N-18) 
 
 
Rabbit (p) 
Rabbit (p) 
Goat (p) 
 
 
1 µg/µl 
1 µg/µl 
1 µg/µl 
 
 
Ab48824 
Sc-894 
Sc-7665 
 
 
Abcam, UK 
Santa Cruz, USA 
Santa Cruz, USA 
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Fig. 2.1 Schematic overview of the generation of Cav-3-loxP mouse strain and of general Cav-3 deficient 
mice. Neo
R
 flanked by two FRT sites was placed in upstream of exon-2 which itself flanked by two loxP sites. 
Mating of FLIP deleter mice with Cav-3-loxP/neoFRT mice caused depletion of neo
R
 locus and generation of 
Cav-3-loxP mice. Further mating of Cav-3-loxP (Flox) mice with Cre deleter mice caused depletion of Cav-3 
exon-2 locus and generation of Cav-3 deficient mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.2 Schematic overview of the protein-protein interaction studies using CO-IP method. The red arrows 
indicate couples of proteins being analyzed for potential interaction. 
 
 
 
 
 
 
cavin-4 
cavin-1 
Cav-3 Cav-1 
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Fig. 2.3 Schematic overview of the videomorphometry method. (A) Briefly, mice are killed by cervical 
dislocation. After opening of the chest, the lungs are filled with low melting point agarose and after cooling 
down cut into 200 µm thick PCLS. After removing the agarose at 37°C one PCLS is transferred into the flow-
through superfusion chamber in which it is exposed to HEPES at 37°C. Constriction is recorded as changes in 
the luminal area. (B) Changes in the luminal area are shown in (a-c). 
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Fig. 2.4 Schematic overview of application schedules of (A) muscarine and (B-D) 5-HT concentrations. 
The concentrations are indicated in molarity and were used in the flow-through superfusion chamber in which 
PCLS were exposed to HEPES at 37°C.  
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Fig. 2.5 Schematic overview of the organ bath recording method. Briefly, mice are killed by inhalation of an 
overdose of isoflurane. After opening of the chest, the airway was cut as shown to four parts (cranial, middle, 
caudal trachea and bronchus). Isolated rings were mounted between two stainless steel clips in organ baths 
exposed to medium gassed with 5% O2. Constriction is recorded as changes in tension or force. 
 
 
 
 
 
 
 
 
 
Fig. 2.6 Schematic overview of application schedules of muscarine and 5-HT concentrations. The 
concentrations are indicated in molarity and were used in the flow-through superfusion chamber in which 
tracheal or bronchial rings were exposed to medium gassed with 5% O2 
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3 Results      
3.1 Cavin isoforms expressed in the murine lung and trachea  
3.1.1 Expression of cavins (1-4) analyzed by RT-PCR in C57BL/6J mice 
The RT-PCR analysis of mRNA isolated from the trachea and lung revealed expression of all 
cavins and β-actin as a housekeeping gene (Fig. 3.1). The mRNA of cavins was consistently 
expressed in all trachea and lung preparations. The identity of the amplified products was 
confirmed by sequencing, and negative controls were run by adding H2O instead of the DNA 
template and absence of reverse transcriptase.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.1 RT-PCR analysis of cavin-1 to -4 in trachea and lung homogenate of C57BL/6J mice. All tested 
trachea and lung preparations were positive for cavin-1 to -4 mRNAs, as shown in the different mice samples. β-
actin as housekeeping gene control was run on all 4 lung and trachea samples. Control reactions included the 
absence of a template (H2O) and the absence of reverse transcriptase (ØRT). M = marker. 
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3.1.2 Expression of cavins analyzed by RT-PCR in tracheal wall compartments 
The RT-PCR analysis of mRNA isolated from abraded tracheal epithelium, tracheal muscle 
and trachea after removing epithelium and muscle revealed expression of cavin-1 and cavin-2. 
Products corresponding to cavin-3 and cavin-4 were not found in the tracheal epithelium, 
although they were easily detectable in tracheal muscle and trachea without epithelium and 
muscle (Fig. 3.2). Negative controls were run by adding H2O instead of the DNA template 
and by omission of the RT step and they were indeed negative. 
3.1.3 Cavin-1 is more abundantly expressed than cavin-4 in lung and trachea of C57BL/6J 
mice 
Real-time PCR analysis of mRNA isolated from trachea, tracheal different parts and lung 
revealed a higher expression of cavin-1 compared to cavin-4 gene expression. CT-values are 
compared to β-actin as a reference gene (Fig. 3.3). 
 
Fig. 3.2 RT-PCR analysis of cavin-1 to -4 in different tracheal wall compartments of C57BL/6J mice. All 
tested tracheal samples were positive for cavin-1 and -2 mRNAs. The mRNA coding for cavin-3 and -4 was 
absent in the tracheal epithelium (TE), but it expressed in tracheal muscle (TM) and trachea without epithelium 
and muscle (TW). Control reactions included the absence of template (H2O) and the absence of reverse 
transcriptase in TM sample (Ø RT). M = marker. 
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Fig. 3.3 Real-time PCR of cavin-1 and cavin-4 in trachea and lung of C57BL/6J mice. ΔCT of cavin-1 and 
cavin-4 mRNAs compared to β-actin are shown for trachea, tracheal epithelium (TE), tracheal muscle (TM), 
trachea without epithelium and muscle (TW) and lung. Lower ΔCT reflects higher expression. As shown for all 
tissue samples, cavin-1 gene expression is significantly higher than cavin-4 gene expression in the samples from 
C57BL/6J mice using the Kruskal-Wallis and Mann-Whitney U-test, n = number of animals.  
 
3.2 Cavin-1 and cavin-4 tissue distribution parallels that of Cav-1 and Cav-3, 
respectively  
3.2.1 Cavin-1 and Cav-1 tissue distribution in thoracic organs that contain Cav-1-dependent 
caveolae 
The expression of Cav-1 and cavin-1 was assessed by immunohistochemistry. Cardiac 
capillary and aortic endothelium served as positive control for Cav-1, demonstrating labelling 
of endothelial cells (Fig. 3.4). Cardiac capillary and aortic endothelial cells were also cavin-1 
immunoreactive (Fig. 3.4). The Cav-1- and cavin-1-antibodies clearly stained tracheal basal 
cells (Fig. 3.4). There was no labelling in the absence of primary antibodies. Similar staining 
patterns with Cav-1- and cavin-1-antibodies were observed in tracheal and bronchial smooth 
muscle cells (SMC) (Fig. 3.4). 
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Fig. 3.4 Cavin-1 and Cav-1 tissue distribution in thoracic organs that contain Cav-1-dependent caveolae. 
Endothelial cells in cardiac capillaries (arrowhead) and aorta (asterisk) are positive for Cav-1 and cavin-1. The 
antibodies to Cav-1 and cavin-1 label tracheal basal cells (double arrow) and SMC (arrow). The antibodies to 
Cav-1 and cavin-1 label bronchial SMC (arrow). Negative controls (neg. contr.) were done by omission of the 
primary antibody. Bar = 50 μm. 
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3.2.2 Cavin-4 and Cav-3 tissue distribution in thoracic organs containing Cav-3-dependent 
caveolae 
The expression of Cav-3 and cavin-4 was assessed by immunohistochemistry. The heart 
served as a positive control for Cav-3-immunolabelling, demonstrating labelling of cardiac 
muscle cells (Fig. 3.5). Cardiac muscle cells were also positive for cavin-4 (Fig. 3.5). Similar 
staining patterns with Cav-3- and cavin-4-antibodies were observed in tracheal and bronchial 
SMC (Fig. 3.5). There was no labelling in the absence of primary antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5 Cavin-4 and Cav-3 tissue distribution in thoracic organs that contain Cav-3-dependent caveolae. 
The antibodies directed against Cav-3 and cavin-4 label cardiac muscle as a positive control (arrowhead). The 
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antibodies to cavin-4 and Cav-3 label tracheal and bronchial SMC (arrow). Negative controls (neg. contr.) were 
done by omission of the primary antibody. Bar = 50 μm. 
3.3 Cav-3 and caveolae peripheral components in primary human bronchial 
smooth muscle cells and human lung  
3.3.1 RT-PCR 
RT-PCR analysis of mRNA isolated from primary human bronchial SMC revealed expression 
of Cav-1, Cav-3, cavin-1 and cavin-4. The mRNAs of cavins were consistently expressed in 
primary human bronchial SMC (Fig. 3.6). The negative controls were done by adding H2O 
instead of the DNA template and by omission of the reverse transcription step. 
 
Fig. 3.6 RT-PCR analysis of Cav-1, Cav-3, cavin-1 and cavin-4 in primary human bronchial smooth 
muscle cells. Positive results were obtained for Cav-1, Cav-3, cavin-1 and cavin-4 mRNAs. Control reactions 
included the absence of template (H2O) and absence of reverse transcriptase (Ø RT). M = marker. 
3.3.2 Immunohistochemistry 
3.3.2.1 Double-labelling immunofluorescence for Cav-1, cavin-1 and cavin-4 with α-SMA 
in human lung   
The protein expression of Cav-1, cavin-1 and cavin-4 was assessed by immunohistochemistry. 
α-SMA-positive bronchial SMC were immunoreactive for Cav-1, cavin-1 and cavin-4 (Fig. 
3.7). Immunofluorescence with antisera directed against Cav-1 showed strong staining of α-
SMA-positive cells, while antibodies to the cavins gave a faint staining (Fig. 3.7).  
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Fig. 3.7 Double-labelling immunofluorescence for Cav-1, cavin-1 and cavin-4 with α-SMA in human 
bronchi. Immunolabelling for Cav-1, cavin-1 and cavin-4 was found in the bronchial SMC (arrow). α-SMA 
fluorescence labelling was also demonstrated in the bronchial SMC (arrow, depicted in the green channel).   
Negative controls (neg. contr.) were done by omission of the primary antibody. In merged images, Cav-1, cavin-
1 and cavin-4 are seen in α-SMA-positive SMC. Selected areas of Cav-1-, cavin-1- and cavin-4-staining 
indicated by blue boxed areas in the left panel are shown at high magnification in the right panel. Bar = 75 µm. 
3.3.2.2 Immunoflorescence labelling for Cav-3 in human lung 
The protein expression of Cav-3 was assessed by immunohistochemistry using rabbit 
polyclonal anti-Cav-1+Cav-3 and mouse monoclonal anti-Cav-3-antibodies. Bronchial SMC 
were immunoreactivite for α-SMA. Immunofluorescence with antisera directed against α-
SMA showed strong staining, while antibodies to Cav-3 gave a faint staining (Fig. 3.8). The 
Nf-68 monoclonal antibody, isotype IgG2, was used as irrelevant antibody isotype control for 
the monoclonal anti-Cav-3-antibody (Fig. 3.8).  
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Fig. 3.8 Immunofluorescence labelling for Cav-3 in bronchial smooth muscle cells of human lung. Cav-1-
Cav-3- and Cav-3-immunoreactivity were found in bronchial SMC (arrow). α-SMA-immunoreactivity was also 
observed in the bronchial SMC (arrow). Isotype control was done by incubation with the monoclonal Nf-68-
antibody. The autofluorescence of the epithelial basal membrane and of connective tissue fibers is indicated by 
arrowheads. Bar = 75 µm.  
3.4 Generation of the Cav-3-loxP-flanked mouse strain and of general Cav-3 
deficient mice 
3.4.1 Genotyping  
DNA extracted from tail snips was analyzed by PCR with different primer sets detecting the 
wild-type and knockout version of the Cav-3 gene as described in section 2.2.2. Samples from 
animals with the wild-type, heterozygous and loxP-flanked Cav-3 gene showed a band of the 
predicted size, and samples from animals that carried the knockout gene did not present any 
band (Fig. 3.9A). To confirm the presence of the knockout allele, we did another PCR with a 
different primer set, and all genotypes of the Cav-3 gene demonstrated a band of the predicted 
size (Fig. 3.9B). Homozygous Cav-3 knockout and wild-type mice were also checked for Cre 
transgene and those with deleted Cre were selected for mating and all sets of experiments 
(Fig. 3.9C). Negative controls were run by adding H2O instead of the DNA template. 
 
 
 
RESULTS 
 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9 PCR genotyping for Cav-3 deficiency. DNA extracted from tail cuts was analyzed by PCR using 
different primer sets. (A) 5/6 primers detected wild-type (w/w) and loxP-flanked Cav-3 gene (p/p) with 
amplicons of 323 and 368 base pairs and no amplicon for Cav-3
-/-
 (d/d) mice. (B) Analyses with 5/12 primers 
detected w/w, p/p and d/d alleles of the Cav-3 gene with 1700, 2000 and 497 bp, respectively. Heterozygous p/w 
showed bands for wild-type and loxP-flanked alleles using both 5/6 and 5/12 primers. (C) PCR analysis with Cre 
primers showed animals carrying the Cre allele (+). Control reaction included the absence of template (H2O). M 
= marker.  
3.4.2 Validation by RT-PCR  
RT-PCR analysis of mRNA isolated from tracheal wall compartments and lung of Cav-3
+/+
 
mice revealed expression of Cav-3 mRNA. Corresponding amplicons were never found in the 
tracheal wall compartments, bronchus, lung and liver of Cav-3
-/-
 mice (Fig. 3.10). The control 
runs without template were negative. 
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Fig. 3.10 RT-PCR analysis of Cav-3 mRNA in Cav-3
+/+
 and Cav-3
-/-
 mice. Samples from Cav-3
+/+
 mice 
consistently express mRNA coding for Cav-3, as shown for bronchus, lung, trachea and tracheal muscle (TM). 
The mRNA coding for Cav-3 is not detected in lung, trachea, liver, TM and trachea without epithelium and 
muscle (TW) in Cav-3
-/-
 mice. Control reactions included the absence of template (H2O), and the absence of 
reverse transcriptase in the trachea (Ø RT). M = marker. 
3.4.3 Validation by immunohistochemistry 
The Cav-3 localization was assessed by immunohistochemistry. Tracheal epithelium and 
SMC were immunoreactive for Cav-3 in Cav-3
+/+
 mice (Fig. 3.11). Bronchial and pulmonary 
arterial SMC were also immunoreactive for Cav-3 in Cav-3
+/+
 mice. Cav-3 staining was 
predominantly localized near the cell membrane. The polyclonal antibody to Cav-3 did not 
show any labelling in Cav-3
-/-
 mice (Fig. 3.11). α-SMA-Immunoreactivity was observed in 
tracheal, bronchial and pulmonary arterial SMC of both strains (Fig. 3.11).  The specificity of 
the Cav-3-antibody was validated by Western blotting (see 3.4.4). 
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Fig. 3.11 Double-labelling immunofluorescence for Cav-3 and α-SMA in Cav-3+/+ and Cav-3-/- mice. Cav-3 
immunoreactivity is seen in the tracheal epithelium (arrowhead), both tracheal and bronchial SMC (double 
arrow) and pulmonary arterial smooth muscle (arrow) in Cav-3
+/+
 mice. α-SMA-immunoreactivity is observed in 
the SMC of trachea, bronchus and pulmonary artery. No Cav-3 labelling is noted in Cav-3
-/-
 mice, although they 
show labelling for α-SMA in trachea and bronchial SMC. Bar = 50 µm. 
3.4.4 Validation by Western blotting 
Crude tissue lysates were loaded onto a 10% polyacrylamide gel in concentrations of 40 
μg/μl, 50 μg/μl and 60 μg/μl (Fig. 3.12 A-C). The gels were stained with Coomassie dye to 
visualize the protein bands. Crude tissue lysate (50 μg/μl) in which all the protein bands were 
well-separated was selected for all Western blots.  
 
Western blotting supported the immunohistochemical findings since the Cav-3-antibody 
recognized Cav-3, a ≈20 kDa band, in protein preparations from Cav-3+/+ mice while it did 
not label a band in protein extracts from Cav-3
-/-
 mice. This immunoblot confirmed the 
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specificity of the Cav-3-antibody (Fig. 3.13). SDH-A was immunolabeled in protein 
preparations from both Cav-3
-/-
 and Cav-3
+/+
 mice as a reference control.  
 
 
 
Fig. 3.12 Selection of protein concentration 
for immunoblots. Crude tissue lysates from 
trachea, bronchus, lung, heart and skeletal 
muscle were loaded onto a 10% 
polyacrylamide gel in (A) 40 μg/μl, (B) 50 
μg/μl and (C) 60 μg/μl concentrations. The gels 
were stained with Coomassie brilliant blue dye. 
Samples were from Cav-3
+/+ 
(+/+) and Cav-3
-/-
 
(-/-) mice. 
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Fig. 3.13 Cav-3 immunoblots. No Cav-3 immunolabelling is present in Cav-3
-/-
 mice samples, while the 
antibody recognizes a single 20 kDa protein band in protein extracts from Cav-3
+/+
 mice samples. Our own 
laboratory polyclonal antibody to SDH-A labels a protein band at 70 kDa in all Cav-3
-/-
 and Cav-3
+/+
 mice 
samples as reference control. 
 
3.5 Cav-3 deficiency: No significant difference in the expression of caveolin and 
peripheral caveolar components in airways 
3.5.1 RT-PCR and real-time PCR  
The mRNAs of cavin-1, cavin-4, Cav-1 and EHD2 were consistently expressed in samples 
from Cav-3
+/+
 and Cav-3
-/-
 mice (Fig. 3.14A). The control runs without template were 
negative. Quantification of relative expression of Cav-1, cavin-1, cavin-4 and EHD2 was done 
by real-time PCR. CT-values were compared to β-actin as reference gene. In Cav-3+/+ mice, 
the Cav-1 expression in tracheal muscle was higher than in Cav-3
-/- 
mice. Otherwise, the 
expression of all tested genes was similar in Cav-3
-/- 
and Cav-3
+/+
 mice (Fig. 3.14B).   
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Fig. 3.14 mRNA expression of cavin-1, cavin-4, Cav-1 and EHD-2 in Cav-3
+/+
 and Cav-3
-/-
 mice. (A) Cavin-
1, cavin-4, Cav-1 and EHD-2 mRNAs were detected by RT-PCR in abraded tracheal epithelium (TE), tracheal 
muscle (TM), trachea, lung and trachea without epithelium and muscle (TW) of both Cav-3
+/+
 and Cav-3
-/-
 
mouse strains. Control reactions for each primer pair included the absence of template (H2O) and absence of 
reverse transcriptase in the lung (Ø RT). (B) Real-time PCR for cavin-1, cavin-4, Cav-1 and EHD-2 in Cav-3+/+ 
and Cav-3
-/-
 mice tissue homogenates, relative expression is presented as ΔCT compared to β-actin. A significant 
difference (Mann-Whitney U-test) between Cav-3
-/-
 and Cav-3
+/+
 mice was seen only for Cav-1 in tracheal 
muscle. Lower ΔCT reflects higher expression. 
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3.5.2 Western blotting 
Blots for the lung, trachea and main bronchus were processed and exposed simultaneously 
(Fig. 3.15A, B), such that the intensity of the bands gives information on the relative 
abundance of Cav-1, cavin-1, cavin-4 and EHD2 compared to β-tubulin in that tissue. There 
were no significant differences between Cav-3
-/-
 and Cav-3
+/+
 mice in the trachea, bronchus 
and lung (Fig. 3.15A).  
Western blotting supported the immunohistochemical findings that Cav-1, cavin-1 and cavin-
4 were detected in the tracheal muscle of both Cav-3
+/+
 and Cav-3
-/-
 mice (Fig. 3.16). In the 
Western blots of tracheal epithelium homogenates, neither cavin-1 and cavin-4 nor Cav-2 
proteins were detected in Cav-3
+/+
 and Cav-3
-/-
 mice (Fig. 3.16). Tubulin as reference control 
was consistently detected in all trachea and bronchus preparations (Fig. 3.16). 
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Fig. 3.15 Expression of Cav-1, cavin-1, cavin-4 and EHD-2 proteins in Cav-3
+/+
 and Cav-3
-/-
 mice. (A) The 
expression of Cav-1, cavin-1, cavin-4 and EHD-2 proteins from Cav-3
+/+
 and Cav-3
-/-
 mice estimated by a 
densitometric analysis of Western blots is presented in the box plots depicting quartiles from 0 to 100. There was 
no significant difference in the mean relative abundance of Cav-1, cavin-1, cavin-4 and EHD-2 to tubulin as 
reference control in the preparations from Cav-3
+/+
 and Cav-3
-/-
 mouse strains using the Mann-Whitney U-test. 
(B) Representative Western blots demonstrating the detection of Cav-1, cavin-1, cavin-4, EHD-2 and tubulin (as 
reference control) in trachea, bronchus, lung and heart homogenate of both mouse strains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.16 Expression of Cav-1, cavin-1, cavin-4 and EHD-2 proteins in tracheal wall compartments and 
bronchus from Cav-3
+/+
 and Cav-3
-/-
 mice. Either cavin-1 or cavin-4 immunolabelling are present in the 
tracheal muscle (TM), bronchus and trachea without epithelium and smooth muscle (TW), while just cavin-4 
antibody recognizes a single protein band in tracheal epithelium (TE).  Cav-1 staining is strong in TM, TW and 
bronchus, while faint in TE. Cav-2 staining is distinct in TM and bronchus, while faint in TW. Tubulin-
immunolabelling is observed in the preparations from Cav-3
+/+
 and Cav-3
-/-
 mice. 
3.5.3 Immunohistochemistry 
The polyclonal antibody to Cav-3 labelled tracheal SMC (arrowhead) and cardiomyocytes of 
the pulmonary vein (arrow) in Cav-3
+/+
 mice (Fig. 3.17). This antibody did not show any 
labelling in tracheal SMC and cardiomyocytes of the pulmonary vein from Cav-3
-/- 
mice (Fig. 
3.17). The specificity of the Cav-3-antibody was further tested by Western blotting (see 
3.4.4). Similar patterns of immunolabeling for Cav-1, cavin-1 and cavin-4 in tracheal muscle 
were observed in both Cav-3
-/- 
and Cav-3
+/+
 mouse strains (Fig. 3.17).  
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Fig. 3.17 Immunolabelling for Cav-3, Cav-1, cavin-1 and cavin-4 in Cav-3
+/+
 and Cav-3
-/-
 mice. Cav-3-
immunoreactivity is seen in tracheal SMC (arrowhead) and cardiomyocytes of the pulmonary vein (arrow) in 
Cav-3
+/+
 mice, but not in Cav-3
-/-
 mice.  Tracheal SMC are Cav-1-, cavin-1- and cavin-4-immunoreactive 
(arrowhead) in both mouse strains. Bar = 50 µm. 
3.6 Interactions of caveolins and cavins 
3.6.1 Cav-1 and Cav-3  
Homogenized tissue lysates containing equal amounts of total protein were incubated with an 
anti-Cav-1-antibody. Antigen-antibody complexes were captured with agarose beads and 
bound proteins solubilized in a SDS sample buffer. Samples from co-immunoprecipitation 
(CO-IP) were resolved by 12% SDS-PAGE, transferred onto a PVDF membrane, and 
analyzed by probing with the antibody against Cav-3. No Cav-3-immunolabelling was present 
in samples from Cav-3
−/−
 mice, while the antibody recognized a single 20 kDa band in 
samples from Cav-3
+/+
 mice, confirming the specificity of the anti-Cav-3-antibody. Heart and 
skeletal muscle were used as CO-IP positive controls.  
 
Fig. 3.18 CO-IP of Cav-1 and Cav-3 in Cav-3
+/+
 (WT) and Cav-3
-/-
 (KO) mice. Immunoprecipitates (IP) with 
Cav-1 are immunoblotted (IB) for Cav-3. Positive CO-IP controls include heart and skeletal muscle from Cav-
3
+/+
 mice. Lung input as intact protein lysate from Cav-3
+/+
 mice is blotted and the expression level of Cav-3 
protein is observed with longer exposure time. The negative control of CO-IP includes beads and antibody in the 
absence of lysate (no sample).  
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3.6.2 Cavin-1 and cavin-4 
Homogenized tissue lysates containing equal amounts of total proteins were incubated with 
the anti-cavin-1-antibody. Samples from CO-IP were resolved by 10% SDS-PAGE, 
transferred onto a PVDF membrane, and analyzed by probing with an antibody against cavin-
4. Cavin-4-immunolabelling was present in samples from the trachea, lung and skeletal 
muscle from Cav-3
+/+
 mice. The antibody recognized a single 35 kDa protein band. In the 
lung input as intact protein lysate from Cav-3
+/+
 mice, only a band at 65 kDa was detected 
(Fig. 3.19A). This could be because of a technical problem and shift of the band in lower 
molecular weights to the right side of the gel and exiting from the gel. Furthermore, we did 
Western blot from the intact protein lysates in a different blot to show cavin-4 expression 
level (Fig. 3.19B). The antibody recognized a 35 kDa protein band in lung input and pooled 
tracheal muscle from Cav-3
+/+
 mice (Fig. 3.19B). In addition, in the highly concentrated lung 
lysate (60 µg/µl), an additional band at 65 kDa was detected which might represent a 
homodimer of cavin-4 (Fig. 3.19B). 
 
 
 
 
Fig. 3.19 CO-IP of cavin-1 and cavin-4 in Cav-3
+/+
 mice. (A) Immunoprecipitates (IP) with cavin-1 are 
immunoblotted (IB) for cavin-4. Skeletal muscle serves as positive control. The negative control of CO-IP is 
done by running beads and antibody in the absence of lysate (no sample). In the lung input as intact protein 
lysate, the band at 65 kDa might represent a cavin-4 dimer. The presence of heavy chains of co-eluted antibody 
in the CO-IP products is observed. (B) Western blots of lysate without immunoprecipitation. The blot visible 
marker is merged and shown on the left using the fusion Fx program. 
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3.6.3 Cav-1 and cavin-1  
Homogenized tissue lysates containing equal amounts of total proteins were incubated with 
the anti-Cav-1-antibody. Samples from CO-IP were resolved by 10% SDS-PAGE, transferred 
onto a PVDF membrane, and analyzed by probing with an antibody against cavin-1. Cavin-1-
immunolabelling was present in the samples from Cav-3
-/-
 and Cav-3
+/+
 mice (Fig. 3.20). The 
antibody recognized a single 60 kDa protein band which was also detected in lysate from 
trachea and lung input of Cav-3
+/+
 mice. The heart and skeletal muscle were used as positive 
controls. In the skeletal muscle, an additional band at 75 kDa was immunolabeled.  
 
 
 
Fig. 3.20 CO-IP of Cav-1 and cavin-1 in the Cav-3
+/+
 (WT) and Cav-3
-/-
 (KO) mice. Immunoprecipitates (IP) 
with Cav-1 are immunoblotted (IB) for cavin-1. CO-IP, representing Cav-1-cavin-1 interaction in all tissue 
homogenates of Cav-3
+/+
 and Cav-3
-/-
 mice. The positive CO-IP controls include heart and skeletal muscle from 
Cav-3
+/+
 mice. The negative control of CO-IP includes beads and antibody in the absence of lysate (no sample). 
The trachea and lung input as intact protein lysate are blotted to show the cavin-1 expression level. 
3.6.4 Cav-3 and cavin-1  
Homogenized tissue lysates from Cav-3
+/+
 mice containing equal amounts of total proteins 
were incubated with the anti-Cav-3-antibody. Samples from CO-IP were resolved by 10% 
SDS-PAGE, transferred onto a PVDF membrane, and analyzed by probing with the antibody 
against cavin-1. Cavin-1-immunolabelling was present in lung and trachea samples. The 
antibody recognized a single 60 kDa protein band (Fig. 3.21). No cavin-1 labeling was present 
in Cav-3-precipitates from skeletal muscle. The lung input as intact protein lysate was blotted 
to show the expression level of cavin-1 protein. 
 
Fig. 3.21 CO-IP of Cav-3 and cavin-1 in the Cav-3
+/+
 mice. Immunoprecipitates (IP) with Cav-3 are 
immunoblotted (IB) for cavin-1. CO-IP, representing Cav-3-cavin-1 interaction in trachea and lung 
homogenates. In skeletal muscle no interaction of Cav-3 and cavin-1 proteins is observed. The negative control 
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of CO-IP includes beads and antibody in the absence of lysate (no sample). The lung input as intact protein 
lysate is blotted to show the cavin-1 expression level. The blot visible marker is merged and shown on the left 
using the fusion Fx program.  
3.6.5 Cav-3 and cavin-4  
Homogenized tissue lysates containing equal amounts of total proteins were incubated with 
the anti-Cav-3-antibody. Samples from CO-IP were resolved by 10% SDS-PAGE, transferred 
onto a PVDF membrane, and analyzed by probing with an antibody against cavin-4. Cavin-4-
immunolabelling was present in Cav-3
+/+
 mice samples. The antibody recognized a single 35 
kDa protein band. Cavin-4-immunolabelling was present in the trachea, lung and very faintly 
in skeletal muscle samples (Fig. 3.22). In the lung lysate, only a band at 65 kDa was detected. 
This could be because of a technical problem and shift of the band in lower molecular weights 
to the right side of the gel and exiting from the gel. 
 
 
 
Fig. 3.22 CO-IP of Cav-3 and cavin-4 in the Cav-3
+/+
 mice. Immunoprecipitates (IP) with Cav-3 are 
immunoblotted (IB) for cavin-4. CO-IP is representing Cav-3-cavin-4 interaction in all tissue homogenates of 
Cav-3
+/+
 mice. The positive CO-IP control includes skeletal muscle which very faintly shows this interaction. 
The negative control of CO-IP includes beads and antibody in the absence of lysate (no sample). In the lung 
input, the band at 65 kDa might represent a cavin-4 dimer. The presense of heavy chains of co-eluted antibody in 
the CO-IP products is observed. The blot visible marker is merged and shown on the left using the fusion Fx 
program.  
 
3.7 Role of Cav-3 for muscarine- and 5-HT-induced constriction in murine 
extrapulmonary airways   
3.7.1 Muscarine-induced constriction  
All segments of extrapulmonary airways, form cranial trachea to main bronchus, exhibited a 
concentration-dependent muscarinic contraction. Neither in absolute force nor in reactivity 
related to KCl-induced contraction (Figs. 3.23-3.26) nor in EC50 (Tab. 3.3), a significant 
difference between airways taken from Cav-3
-/-
 and Cav-3
+/+
 mice was observed. In both 
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strains, the contraction evoked by 10
-5
 M muscarine was not significantly enhanced further at 
higher concentrations in all segments. 
 
 
 
Fig. 3.23 Muscarine-induced contraction of cranial trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 
muscarine. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. 
Data are presented as mean ± SEM. In neither parameter, a significant difference between samples from Cav-
3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test).
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Fig. 3.24 Muscarine-induced contraction of middle trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 
muscarine. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. 
Data are presented as mean ± SEM. In neither parameter, a significant difference between samples from Cav-
3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test).
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Fig. 3.25 Muscarine-induced contraction of caudal trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 
muscarine. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. 
Data are presented as mean ± SEM. In neither parameter, a significant difference between samples from Cav-
3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test).
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Fig. 3.26 Muscarine-induced contraction of main bronchus from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 
muscarine. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. 
Data are presented as mean ± SEM. In neither parameter, a significant difference between samples from Cav-
3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test).
 
 
3.7.2 5-HT-induced constriction  
All segments of trachea in Cav-3
+/+
 mice, form cranial to caudal part, exhibited a 
concentration-dependent 5-HT-induced contraction. In Cav-3
-/-
 mice, higher concentrations of 
5-HT were needed to induce a response in the cranial trachea (Figs. 3.23). This response was 
significantly lower than in Cav-3
+/+
 mice at a concentration of (10
-5
 M) in reactivity level. 
Both in absolute force and in reactivity related to KCl-induced contraction, there was 
practically no 5-HT-induced response in tracheal middle, caudal and main bronchus in Cav-3
-
/-
 mice (Figs. 3.24-3.26). The main bronchus from Cav-3
+/+
 mice showed high variability in 
the 5-HT-induced response and this variation caused a big deviation.  
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Fig. 3.27 5-HT-induced contraction of cranial trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 5-
HT. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. Data 
are presented as mean ± SEM. There was no 5-HT-induced response in Cav-3
-/-
 mice measured in force 
recording. In the reactivity parameter, a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice 
was observed.  Mann-Whitney U-test conducted after Kruskal-Wallis test with p ≤ 0.05, p values indicated in B. 
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Fig. 3.28 5-HT-induced contraction of middle trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 5-
HT. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. Data 
are presented as mean ± SEM. There was no clear 5-HT-induced response in Cav-3
-/-
 mice measured in force 
recording. In the reactivity parameter, a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice 
was observed. Mann-Whitney U-test conducted after Kruskal-Wallis test with p ≤ 0.05, p values indicated in B; 
C and D, * p ≤ 0.05. 
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Fig. 3.29 5-HT-induced contraction of caudal trachea from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 5-
HT. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. Data 
are presented as mean ± SEM. There was no clear 5-HT-induced response in Cav-3
-/-
 mice measured in force 
recording. In the reactivity parameter, a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice 
was observed. Mann-Whitney U-test conducted after Kruskal-Wallis test with p ≤ 0.05, p values indicated in B; 
C and D, * p ≤ 0.05, ** p ≤ 0.01. 
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Fig. 3.30 5-HT-induced contraction of main bronchus from Cav-3
+/+
 and Cav-3
-/-
 mice in organ bath 
experiments. Concentration-dependent responses are shown as maximum reaction in force (A) and reactivity 
related to KCl-induced contraction (B), and as force developed 1 min (C) and 10 min (D) after application of 5-
HT. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set as 100%. Data 
are presented as mean ± SEM. There was no 5-HT-induced response in Cav-3
-/-
 mice measured in force 
recording. In the reactivity parameter, a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice 
was observed.  Mann-Whitney U-test conducted after Kruskal-Wallis test with p ≤ 0.05, p values indicated in B; 
D, * p ≤ 0.05. 
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Tab. 3.3 EC50 of muscarine- and 5-HT-induced contraction in Cav-3
+/+
 and Cav-3
-/-
 mice. EC50 values 
were estimated by using nonlinear regression sigmoidal curve analysis for responses to muscarine and 5-HT, 
respectively. No significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice in response to 
muscarine was observed (Mann-Whitney U-test). 5-HT-induced responses are fully abrogated in bronchus, 
middle and caudal trachea from the Cav-3
-/-
 strain.  
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Fig. 3.31 Muscarine- and 5-HT-induced contraction in extrapulmonary airways of Cav-3
+/+
 and Cav-3
-/-
 
mice in organ bath experiments. Concentration-dependent responses are shown in force of Cav-3
+/+
 (A) and 
Cav-3
-/-
 mice (B), after cumulative application of muscarine and 5-HT. These curves also illustrate the basis of 
the Figs. 3.23-3.30.  KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value was set 
as 100%. Data are presented as mean ± SEM. In neither mouse strain, a significant difference between samples 
from different segments was observed (Mann-Whitney U-test). 
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3.8 Role of Cav-3 for muscarine- and 5-HT-induced constriction in murine 
intrapulmonary airways 
3.8.1 Muscarine-induced constriction 
Intrapulmonary bronchi exhibited a concentration-dependent muscarinic contraction measured 
as decrease in luminal airway area (Fig. 3.32A, B). The muscarine-induced constriction 
started at 10
-8
 M (p=0.02) in Cav-3
+/+
 mice and at 5 × 10
-8
 M (p=0.02) in Cav-3
-/-
 mice.  
However, compared with bronchi from wild-type animals (EC50: 1.14 ± 1.11 µM), Cav-3 
deficiency (EC50: 0.038 ± 0.02 µM) caused an increase in the muscarine-induced 
bronchoconstriction at concentrations of 5 × 10
-6
 M - 5 × 10
-5
 M (Fig. 3.32C-D). In Cav-3
+/+ 
and Cav-3
-/-
 mice, the contraction evoked by 5 × 10
-7
 M and 5 × 10
-6
 M (p=0.04) muscarine, 
respectively were not significantly enhanced further at higher concentrations (Fig. 3.32B-D). 
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Fig. 3.32 Muscarine-induced constriction of intrapulmonary bronchi from Cav-3
+/+
 and Cav-3
-/-
 mice in 
video morphometry experiments. Concentration-dependent responses are shown as maximum reduction in the 
luminal area of mouse peripheral airways (A-B) and as luminal area at 1 min (C) and 10 min (D) after 
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application of muscarine. KCl (60 mM) was applied as a viability control for 5 min, and the prestimulus value 
was set as 100%. Data are presented as mean ± SEM. A significant difference between samples from Cav-
3
+/+
 and Cav-3
-/-
 mice was observed (p-value calculated by Mann-Whitney U-test conducted after Kruskal-Wallis 
test with p ≤ 0.05). Bar in (A) = 500 μm. 
 
3.8.2 5-HT-induced constriction  
To test for a desensitizing effect of 5-HT during cumulative application, three different 
application schedules were chosen. Intrapulmonary bronchi exhibited a concentration-
dependent contraction in response to stimulation with gradually increasing concentrations (10
-
7
-10
-3 
M in half logarithmic mode) of 5-HT (Fig. 3.33A-B). The 5-HT-induced constriction 
started at 10
-7
 M in both Cav-3
+/+
 mice (p=0.02) and in Cav-3
-/-
 mice (p=0.05). The 
contraction evoked by 10
-5
 M in Cav-3
+/+
 (EC50: 0.025 ± 0.006 µM, p=0.04) and in Cav-3
-/-
 
mice (EC50: 0.1 ± 0.03 µM, p=0.01) was not significantly enhanced further at higher 
concentrations. However, compared with bronchi from wild-type animals, Cav-3 deficiency 
had no effect on the 5-HT-induced bronchoconstriction (Fig. 3.32B-D). 
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Fig. 3.33 5-HT-induced constriction of intrapulmonary bronchi from Cav-3
+/+
 and Cav-3
-/-
 mice in video 
morphometry experiments. Concentration-dependent responses are shown as maximum reduction in the 
luminal area of mouse peripheral airways (A-B) and as luminal area at 1 min (C) and 10 min (D) after 
application of cumulative concentrations of 5-HT (10
-7
-10
-3
 M). KCl (60 mM) was applied as a viability control 
for 5 min, and the prestimulus value was set as 100%. Data are presented as mean ± SEM. At neither time point, 
a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test). 
Bar in (A) = 500 μm. 
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Intrapulmonary bronchi also exhibited a concentration-dependent contraction in response to 
stimulation with less repetitive 5-HT stimulation (10
-6
-10
-4
 M) (Fig. 3.34A-B). Compared 
with bronchi from wild-type animals, Cav-3 deficiency had no effect on the 5-HT-induced 
bronchoconstriction (Fig. 3.34C-D).  
 
 
Fig. 3.34 5-HT-induced constriction of intrapulmonary bronchi from Cav-3
+/+
 and Cav-3
-/-
 mice in video 
morphometry experiments. Concentration-dependent responses are shown as maximum reduction in the 
luminal area of mouse peripheral airways (A-B) and as luminal area at 1 min (C) and 10 min (D) after 
application of 5-HT (10
-6
-10
-5
-10
-4
 M). KCl (60 mM) was applied as a viability control for 5 min, and the 
prestimulus value was set as 100%. Data are presented as mean ± SEM. At neither time point, a significant 
difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test). Bar in (A) = 
500 μm. 
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Stimulation with 10
-4
 M 5-HT followed by application of supramaximal concentration of 5-
HT, 10
-3 
M also resulted in a concentration-dependent contraction (Fig. 3.35A-B). 
Intrapulmonary bronchi responded to 10
-4 
M 5-HT with an initial rapid constriction (p=0.01) 
in both mouse strains and with a sustained constriction at 10
-3 
M. Compared with bronchi 
from wild-type animals, Cav-3 deficiency had no effect on the 5-HT-induced 
bronchoconstriction (Fig. 3.35B-D). 
 
Fig. 3.35 5-HT-induced constriction of intrapulmonary bronchi from Cav-3
+/+
 and Cav-3
-/-
 mice in video 
morphometry experiments. Concentration-dependent responses are shown as maximum reduction in the 
luminal area of mouse peripheral airways (A-B) and as luminal area at 1 min (C) and 10 min (D) after 
application of cumulative concentrations of 5-HT (10
-4
-10
-3 
M). KCl (60 mM) was applied as a viability control 
for 5 min, and the prestimulus value was set as 100%. Data are presented as mean ± SEM. At neither time point, 
a significant difference between samples from Cav-3
+/+
 and Cav-3
-/-
 mice was observed (Mann-Whitney U-test). 
Bar in (A) = 500 μm. 
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4 Discussion 
4.1 Caveolae and the caveolar compartment structure 
Caveolae are defined by a set of core protein ingredients, Cav, which govern their structure 
and function [59]. Although the presence of at least one of the caveolin family members, Cav-
1 and Cav-3, is indispensable for caveolae formation in mammalian cells [8, 11-19, 22, 23], 
recent data suggest that certain accessory molecules, cavins, are necessary for stabilizing Cav-
1 or Cav-3 functions and to form a caveola [8, 58]. Caveolins and cavins can be purified as a 
single species of protein complex named the caveolar coat complex [149]. The discovery of 
the cavin family as regulators of caveolae formation and stabilization has provided new 
insights to understand the role of muscle caveolae. 
4.1.1 Cavin-1 and -4 distribution patterns indicate their involvement in Cav-1- and Cav-3-
dependent caveolae formation 
The present data show the expression of all four cavin proteins in murine trachea and lung, 
suggesting an important role in these tissues. Accordingly, Govender et al. [150] have noted 
pronounced alterations in pulmonary homeostasis after targeted deletion of cavin-1. They 
detected cavin-1 in alveolar macrophages, endothelial cells and type I pneumocytes.  Deletion 
of cavin-1 led to a complex lung phenotype including marked hypercellularity, increased 
elastance and deposition of extracellular matrix as well as decreased levels of granulocyte-
monocyte colony-stimulating factor (GM-CSF) which is critical for surfactant phospholipid 
catabolism and the clearance of pathogens from the lung [150]. 
In agreement with the findings of Govender et al. [150], we did not observe cavin-1-
immunoreacitvity of the bronchial epithelium, but noted expression of both cavin-1 and -2 in 
the tracheal epithelium. Immunohistochemistry showed that cavin-1 is restricted to basal cells 
in the tracheal epithelium which explains the absence of cavin-1 from the bronchial 
epithelium which does not contain basal cells in the mouse. Real-time PCR demonstrated that 
the tracheal SM expresses all cavin isoforms, cavin-1 to -4. Bastiani et al. showed a dominant 
presence of cavin-4 in cardiac and skeletal muscles and clearly lower level of cavin-4 
expression in other cell types [58]. Our observations also indicate that cavin family members, 
key components of caveolae, show a tissue-specific expression. Cavin-1 expression was 
higher than cavin-4 in the lung and tracheal wall compartments. Among the cavins, cavin-1 is 
required for caveolae formation in various cell types including epithelium, SM, and skeletal 
muscle [58, 68, 71]. This need for cavin-1 might explain its higher expression compared to 
that of cavin-4 in tracheal wall compartments and the lung.  
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In view of the tissue-specific expression of cavin proteins and their dependency on caveolins 
for membrane association, we assessed the localization of these two protein families in 
thoracic organs that contain Cav-dependent caveolae. We found that Cav-1 and cavin-1 co-
localize in the tracheal basal epithelium, tracheal and bronchial SMC and endothelial cells. In 
agreement with this observation, cavin-1 has been shown to co-localize with Cav-1 in primary 
rat and 3T3-L1 cultured adipocytes, and the cavin-1 level, like that of Cav-1, is sensitive to 
cholesterol depletion [151]. Animals lacking cavin-1 have no detectable caveolae in any cell 
type and have a diminished protein content of all caveolin isoforms while a normal or above 
normal level of caveolin mRNA expression is retained [71]. We here show cavin-4 and Cav-3 
to be co-localized in cardiac muscle cells and SMC from trachea and bronchi consistent with 
previously reported co-expression of cavin-4 and Cav-3 in human and mouse 
rhabdomyosarcoma [79]. Since Cav-3-deficient muscles from dystrophic patients display a 
loss of cavin-4, Cav-3 and cavin-4 may co-operate in maintaining proper function in the 
skeletal muscle [58, 79].  
Consistent with our findings in mice, expression of all cavins was observed in primary human 
bronchial SMC using RT-PCR. Immunohistochemistry confirmed the presence of cavin-1 and 
-4 proteins in human bronchial SMC. The functional role of cavins in human airways is still 
poorly understood. In isolated human ASM, knockdown of either cavin-1 or cavin-3 by 
siRNA reduced ADP ribosyl cyclase activity and the expression of CD38, a bifunctional 
enzyme involved in cyclic ADP ribose metabolism. This had consequences on airway 
contractility as it reduced the histamine-induced increase in [Ca
2+
]i [152]. The relevance of 
this in vitro finding for overall bronchial functions still needs to be clarified, since patients 
with cavin-1 mutations present with lipodystrophy and signs of skeletal muscle dystrophy, but 
smooth muscle dysfunction has not been reported yet [21].  
Confirming previous data from our group, Cav-1 and Cav-3 were identified in mouse and 
human ASM on mRNA and protein levels in the present study [16, 105]. In contrast, the 
absence of Cav-3 in isolated human ASM and freshly dissected trachealis muscle was 
reported by other groups [18, 102, 136]. This discrepancy might be due to the different 
antibodies used for the detection and/or to alteration of Cav-3 expression by isolation of 
ASM. While functional data on the role of Cav-3 are still missing for human ASM, the 
present study revealed a functional impact of Cav-3 deficiency on murine airway contractility, 
thereby supporting the presence of Cav-3 in ASM.  
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4.1.2 Caveolae abundance and cavin expression are not reduced in airways of Cav-3-/- mice 
Cav-3 is important for the transition from synthetic to contractile phenotype in vascular SMC 
[41, 153]. With this context in mind and in view of the dominant expression of Cav-3 in other 
muscle cells (cardiac and skeletal), we reasoned that Cav-3 might also organize caveolar coat 
complex and structure in ASM. To address this issue directly, we created a caveolin-3-
deficient (Cav-3
-/-
) mouse model, using loxP/Cre technology. This strategy gives the option to 
generate cell type-specific knockouts by expressing Cre under the control of cell type-specific 
promotors. Here, we first generated a global Cav-3 deficient mouse strain by cross-breeding 
with a Cre-deleter mouse line, in which Cre expression is driven in every cell type under the 
control of the adenovirus EIIa promoter. Previous studies also have generated Cav-3
-/-
 mice 
using standard homologous recombination techniques [45, 154]. All Cav-3
-/-
 mice generated  
so far, including ours and those reported by Galbiati et al. and Hagiwara et al. [45, 154], are 
designed by targeting exon-2 of the Cav-3 gene which encodes the bulk of the Cav-3 protein 
with all of its functional domains. These mice are viable, fertile and exhibit normal growth 
under normal conditions even into old age. The most notable pathological findings in Cav-3 
deficiency reported by Hagiwara were muscle fiber necrosis in muscular dystrophies and 
pathological lesions mainly in the soleus muscle and the diaphragm [45]. Galbiati et al. 
showed mild myopathic changes in Cav-3 null mice which were similar in severity to those 
seen in patients with limb girdle muscular dystrophy caused by mutations within the coding 
sequence of the exon-2 of the Cav-3 gene [77, 154]. Ultra-structural analysis of skeletal 
muscle from our Cav-3
-/-
 mice, which was done by M. Skill in our group, also revealed mild 
myopathic changes with variability in the size of necrotic fibers in the cytoskeletal 
architecture of muscle tissue that is characteristic of muscular dystrophy [submitted].  
RT-PCR, Western blotting, and immunohistochemistry of a range of tissues confirmed that 
the Cav-3 mRNA and protein are indeed absent in the Cav-3
-/-
 mice. Cav-1 deficiency leads to 
Cav-2 destabilization in the Cav-1-dominated caveolae so that, despite normal Cav-2 mRNA 
expression, Cav-2 protein is no longer detectable in the lung [155]. Such an effect was not 
observed for the newly generated Cav-3 deficient mouse line. The expression of all other 
caveolins and peripheral caveolar components was maintained in all investigated airway and 
lung compartments as assessed by Western blot and real-time PCR. The only alteration which 
we observed was a significant reduction in Cav-1 mRNA level which, however, did not 
translate into detectable changes in Cav-1 protein. There was no alteration in other caveolin 
and peripheral caveolar coat complex mRNA expression in Cav-3
-/-
 animals as assessed by 
real-time PCR. Although Cav-3 and cavin-4 are co-localized and interact in murine airways, 
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there was no detectable change in cavin-4 when Cav-3 is deleted indicating that Cav-3 is 
dispensable for stabilization of cavin-4 in ASM. In contrast, Ogata et al. showed diminished 
membrane localization of cavin-4 in cardiomyocytes when Cav-3 was knocked down [156] 
pointing towards cell-type specific interaction patterns governing trafficking and stabilization.  
Although cavins are dependent on caveolins for membrane association, we were able to detect 
cavin-1, cavin-4 and Cav-1 in both Cav-3
-/-
 and Cav-3
+/+
 mice by immunohistochemistry and 
Western blotting, suggesting that the caveolar coat complex is not dependent on Cav-3 in 
ASM. Our quantitative data on the caveolar abundance marker, EHD-2, imply that Cav-3 
does not contribute to the abundancy of ASM caveolae, and caveolae are still present in Cav-
3
-/-
 mice. This is corroborated by electron microscopic analysis of tracheal SMC by M. Skill 
in our group, revealing no alteration in caveolae numbers in Cav-3
-/- 
mice [submitted]. In 
contrast, Cav-3 as shown in previous studies regulates caveolar formation in cardiac and 
skeletal muscle cells, indicating that the Cav-3 deficiency leads to decreased numbers or the 
absence of caveolar structures, with associated T-tubular disorganization and dramatic 
cardiomyopathy [45, 46, 154, 157, 158]. In addition, several studies using transgenic mice 
overexpressing Cav-3 revealed an increased number of sarcolemmal muscle cell caveolae in 
skeletal muscle fibers and cardiomyocytes [146, 159]. Thus, there are obvious differences 
between smooth and striated muscle, and it is expected that specific aspects of caveolar 
function rather than caveolar abundancy are dependent on the expression of Cav-3 in tracheal 
SMC. In addition to Cav-3, Cav-1 is also expressed in ASM. Since we recently observed a 
decreased number of caveolae in tracheal SMC in Cav-1
-/-
 mice in ultra-structural analysis 
[submitted], Cav-1 appears to be crucial for caveolae abundancy and caveolar morphogenesis 
in tracheal SMC.  
4.1.3 Cav-3 interacts with Cav-1, cavin-1 and cavin-4 in ASM  
Double-labelling immunohistochemistry demonstrated the occurrence of multiple Cav and 
cavin isoforms in ASM, suggesting interaction in multimeric complexes. This issue was 
further addressed by CO-IP experiments, centering on the role of Cav-3. Cav-1/Cav-3 hetero-
oligomeric complexes have previously been observed in rat and mouse cardiomyocytes, 
mouse myoblasts and skeletal muscle of Cav-1-overexpressing mice [39, 40]. Accordingly, 
both caveolins were co-immunoprecipitated also in extracts from lung and trachea in the 
present study. This corroborates earlier findings from our group showing interaction of Cav-1 
and Cav-3 by antibody based FRET (fluorescence resonance energy transfer) analysis by 
confocal laser scanning microscopy [16]. Similarly, cavin-4 has been shown to localize in 
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cardiomyocyte caveolae and to associate with other caveolae-associated proteins, including 
Cav-3 [65, 156]. This interaction appears not to be restricted to cardiac muscle since we 
observed Cav-3/cavin-4 CO-IP also in lung and trachea in the present study. It is likely that 
Cav-3/cavin-4 also interact in skeletal muscle since they are co-expressed in large quantity, 
and cavin-4 mislocalizes in skeletal muscle fibers from patients with caveolopathies [58], but 
this still needs to be demonstrated directly. 
A newly recognized interaction under physiological conditions was noted for Cav-3 and 
cavin-1, which previously had been noted only after plasmid transfection [156]. Since cavin-1 
mRNA was much more abundant than cavin-4 mRNA in ASM, cavin-1 might be the 
dominant interaction partner of Cav-3 in this tissue. Also, cavin-1 has previously been shown 
to be essential for caveolae formation and organization and to associate with Cav-1 or Cav-3 
to drive caveolae formation in non-muscle and muscle cells, respectively [68, 151]. 
Accordingly, cavin-1 mutations lead to muscular dystrophy and cardiac dysfunction [20], and 
overexpression of this caveolae-associated protein rescues membrane repair defects in 
dystrophic muscle [160].  
Since Cav-3 co-immunoprecipitated and co-localized with Cav-1, cavin-1 and cavin-4 in 
ASM, multimeric complexes consisting of all these caveolar coat complex proteins appeared 
to be likely. We directly addressed this question by CO-IP experiments. Equivocal findings 
have previously been reported for Cav-1/cavin-1 interaction. Liu et al. failed to see a direct 
interaction between Cav-1 and cavin-1 by CO-IP suggesting no direct interaction or weak 
interaction between them in adipocytes [151]. On the other hand, cavin-1 strongly interacts 
with Cav-1 in transfected Hela cell line to stabilize Cav-1 oligomers [149]. Upon 
overexpression of cavin-1 in the HEK293 cell line, Cav-1 recruitment into lipid raft fractions 
was apparently increased, and upon knockdown of cavin-1, Cav-1 was downregulated in 3T3-
L1 cell lysates [151]. In lung and trachea, we detected distinct cavin-1/Cav-1 interaction, 
pointing towards cell-type specific interaction patterns. This interaction was similarly seen by 
CO-IP in the trachea and lung of both Cav-3
-/-
 and Cav-3
+/+
 mice, suggesting that the complex 
formation is not dependent on Cav-3, albeit both also co-immunoprecipitated with Cav-3. 
Lastly, CO-IP revealed that the heteromeric protein complex in lung and trachea also 
contained both cavin-1 and cavin-4 proteins. However, despite the individual abilities of both 
cavin-1 and -4 to shape heteromeric complex in the cytoplasm prior to association with 
caveolin on the plasma membrane [59], further studies with caveolae buoyant fractions are 
required to test if this cavin complex is inserted into the membrane in this composition. 
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4.2 Role of Cav-3 in airway smooth muscle constriction 
A wide range of contractile stimuli are acting either directly on ASM or indirectly through 
neural pathways leading to airway hyperreactivity [84]. Several GPCR including 5-HT and 
MR are aggregated at caveolae structures [14, 82]. Dysregulation of caveolae and caveolins is 
assumed to be involved in the pathogenesis of diseases associated with airway hyperreactivity 
[161]. In the past, a large number of signaling molecules were co-purified with Cav-3 
suggesting that Cav-3 containing caveolae are involved in intracellular signaling [162], and 
Cav-3 has recently also identified in ASM [16].  Thus, knowing the regulatory role of Cav-3 
in the constrictor response to contractile stimuli may provide an opportunity to modulate 
bronchial hyperreactivity.  
4.2.1 Muscarine-induced constriction is enhanced in intrapulmonary airways of Cav-3-/- mice  
ACh is the major physiological bronchoconstrictor and its effect is mediated primarily 
through the M3R and, to a lesser extent, through the M2R receptor subtype [89]. Several 
evidences accumulated that this muscarinic bronchoconstriction involves caveolae as 
signaling platforms. In murine intrapulmonary airways, muscarine-induced 
bronchoconstriction is largely reduced by pretreatment with the cholesterol depleting agent 
MCD which causes ultrastructural disappearance of caveolae from bronchial ASM [16]. 
Interactions of the M3R with caveolins appear likely but could not be directly investigated in 
ASM due to the lack of M3R specific antibodies as demonstrated using tissues from M3R 
knockout mice [163, 164]. The M2R directly interacts with Cav-3, but not Cav-1 in murine 
ASM, as shown by antibody based confocal FRET analysis [16]. On this background, the 
generation of a Cav-3 gene deficient mouse was initiated, and the prediction was that 
muscarinic bronchoconstriction will be diminished in this condition. 
In contrast to this expectation, the response of all extrapulmonary airway segments (cranial to 
caudal trachea, extrapulmonary bronchus; assessed in organ bath recordings) to muscarine 
was indistinguishable in Cav-3
-/-
 from Cav-3
+/+
 mice, regardless whether EC50, force or 
reactivity was considered. In intrapulmonary bronchi, assessed by videomorphometry of 
PCLS, however, our findings show a considerable increase rather than decrease in muscarinic 
bronchoconstriction in Cav-3
-/-
 mice. This demonstrates an unexpected inhibitory regulatory 
role of Cav-3 in cholinergic bronchoconstriction. In agreement with this finding, overactivity 
of SM was also reported in the rat urinary bladder with age and ascribed to a reduction in 
Cav-3 protein expression [144, 165]. The direct association between M2R and Cav-3 in 
murine bronchial SMC [16] suggests that this inhibition targets the M2R signaling pathway. 
The underlying molecular pathways are still unclear and cannot be finally deduced from the 
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present data. Cav-3 may inhibit MR function by direct interaction, or organize MR-
independent inhibitory signaling. Findings on other cellular systems point to a link to nitrergic 
signaling. Using FRET analysis, we have previously demonstrated a direct association of 
Cav-3 and eNOS in rat airway epithelial cells [105]. In cardiac myocytes and in transfected 
COS cells co‐expressing the M2R and eNOS, stimulation with carbachol leads to NO 
production [166-168]. In this setup, Cav-3 suppresses basal eNOS activity but is 
indispensable for cholinergic activation of eNOS. The disruption of the inhibitory eNOS-Cav-
3 complex, e.g. with an oligopeptide corresponding to the Cav-3 scaffolding domain, 
completely abrogates cholinergic stimulation of eNOS with subsequent elevation of cGMP 
levels [166, 167]. In ASM, NO is a bronchodilator acting through cGMP-dependent and -
independent mechanisms [169], and NO production by ASM itself can be stimulated by the 
cholinergic agonist carbachol at low concentration acting via the M2R [170]. Hence, it seems 
to be a plausible scenario that cholinergic stimulation of ASM not only activates a strong 
constrictor pathway but also an inhibitory component involving M2R-Cav-3-eNOS coupling. 
In such a setting, selectively removing Cav-3, as it is the case in Cav-3 deficient mice, would 
abrogate the inhibitory component, resulting in enhanced cholinergic constriction, whereas 
disruption of the entire signaling platform by MCD treatment would also affect the constrictor 
component, as reported earlier [16]. This would imply that Cav-3 is either not involved at all 
in this constrictor response or at least dispensable and its function might be compensated by 
Cav-1 in this pathway. Indeed, we also observed a hetero-oligomeric complex of Cav-1 and 
Cav-3 in trachea and lung by CO-IP. Cav-1/Cav-3 hetero-oligomeric complexes were also 
observed in rat and mouse myocytes of Cav-1-overexpressing mice [39, 40]. Several proteins 
binding to Cav-3 are also able to interact with Cav-1 [36, 171], suggesting that Cav-3 might 
be exchangeable with Cav-1. Considering the dependency of muscarinic constriction on intact 
caveolae, further functional studies with Cav-1/Cav-3-deficient mice or cavin-1-deficient 
mice which exhibit phenotypes reminiscent of Cav-1 and Cav-3-deficient mice [172] are 
necessary to solve this. 
Notably, this augmentation of cholinergic bronchoconstriction in Cav-3 deficiency was not 
noted in organ bath recordings from extrapulmonary airways. This difference to 
intrapulmonary airways in PCLS may be due to different receptor coupling in extra- versus 
intrapulmonary airways. In support of this assumption, the total densities of several receptors, 
including both MR and β-AR, vary considerably along the airway tree from the trachea to the 
distal lung [89]. M3R-ligand binding density decreased from the segmental to subsegmental 
bronchus whereas the M2R subtype was distributed ubiquitously, and β2-AR increased along 
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the airways towards the periphery [89]. Of course, it also cannot be excluded that the different 
methodological approaches to record ASM constriction - force recording in organ bath versus 
videomorphometry of PCLS - may have contributed substantially to this difference. 
4.2.2 5-HT-induced constriction is largely dependent on Cav-3 in extrapulmonary airway 
The effects of 5-HT on ASM tone are complex, and both constrictor and relaxant actions have 
been reported depending on species and concentrations used. In humans, bronchoconstriction 
is ascribed to 5-HT2A receptors and bronchodilation to 5-HT1A receptors on smooth muscle 
[112]. Since free 5-HT levels in plasma are increased in asthma, it has been linked to 
pathophysiology of this disease [112, 113]. In mice, different modes of action of 5-HT have 
been reported for extra- and intrapulmonary airways, respectively. In the trachea, 5-HT is 
assumed to cause the release of ACh either from epithelial cells [173] or from cholinergic 
nerve fibers [174, 175] which then, in turn, causes airway constriction. In intrapulmonary 
airways, however, serotonergic bronchoconstriction is independent from the presence of M3R 
receptors and, therefore, not indirectly mediated via ACh [107]. 
Similarly, marked differences between extra- and intrapulmonary airways were also noted in 
the present study, in that the 5-HT-mediated constriction was equally strong in 
intrapulmonary airways of knockout and wild-type mice while it was absent in 
extrapulmonary airways of Cav-3
-/-
 mice. Serotonergic airway constriction in murine 
extrapulmonary is considered to be indirectly mediated through ACh release from epithelial 
cells or nerve fibers [173-175]. Since muscarinic constriction of extrapulmonary airways was 
unaffected in Cav-3
-/-
 mice, the cholinergic component of this indirect effect shall not be 
responsible for the abrogated serotonergic effect. Among the suspected immediate targets of 
5-HT, cholinergic neurons and epithelial cells, there is no clear evidence for Cav-3 expression 
in autonomic neurons, although our group has previously reported Cav-3 expression in 
sensory neurons [176]. However, we here directly observed Cav-3 in tracheal epithelial cells, 
consistent with earlier reports of our group in rat [155]. Notably, we did not observe Cav-3-
immunoreactivity in the epithelium of intrapulmonary bronchi, which correlates with the 
unaffected serotonergic response at this airway level.  
In intrapulmonary bronchi, a large portion of the reaction to 5-HT is due to direct action upon 
the smooth muscle. In a parallel study we showed expression of the 5-HT receptor subtypes 5-
HT1B, 5-HT2A, 5-HT6 and 5-HT7 in murine lung, and the 5-HT2A receptor inhibitor 
ketanserine inhibited 5-HT-induced constriction in murine PCLS [submitted]. Also, in other 
species the 5-HT2A receptor has been linked to direct serotonergic smooth muscle 
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constriction [112, 123]. The 5-HT2A receptor was shown to be located in caveolar and non-
caveolar fractions in bovine ASM and in cardiomyocytes. In cardiomyocytes, Cav-3 regulates 
its shift between caveolar and lipid raft membrane compartments [114, 120, 162]. There, it 
associates with the 5-HT2A receptor and negatively regulates hypertrophic response of 
cardiomyoblasts and neonatal cardiomyocytes to 5-HT [120]. Despite this known interaction 
of Cav-3 with 5-HT2A receptors, Cav-3 deficiency did not affect serotonergic intrapulmonary 
bronchoconstriction in this study, whereas disruption of the entire signaling platform by MCD 
treatment entirely abrogated it, as reported earlier [16]. This implies that a cholesterol-rich 
membrane domain, most likely a caveola is needed for serotonergic bronchoconstriction, but 
Cav-3 is not involved at all in this response or at least dispensable. 
Although Cav-3 expression in rat tracheal epithelium or murine sensory neurons was 
previously observed [155, 176] or its expression in apical membrane of epithelial cells in this 
study support Cav-3 role in indirect, ACh induced, serotonergic response.  
4.3 Conclusions 
The present study identifies Cav-3 as a member of the caveolar coat complex in the airways 
which determines specific functions in this signaling platform albeit being dispensable for 
structural maintenance of this compartment. Its role in regulating cholinergic airway 
constriction is restricted to intrapulmonary bronchi. Here, it exerts an inhibitory role, probably 
through its interaction with M2R-eNOS coupling in ASM. In contrast to its rather subtle role 
in modulation of cholinergic bronchoconstriction, Cav-3 is crucial for serotonergic 
constriction of extrapulmonary airways, where it is also expressed by epithelial cells. These 
epithelial cells are assumed to mediate serotonergic constriction of the trachea. The absence 
of Cav-3 from epithelial cells of intrapulmonary bronchi correlates with unaltered 
serotonergic response of these airways in Cav-3
-/-
 mice. Potentially, these data warrant 
consideration during pharmacological modulation of the cholinergic and serotonergic 
responses and provide an opportunity to modulate airway hyperreactivity.
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5 Summary 
Acetylcholine (ACh) and serotonin are bronchoconstrictors clinically relevant in airway 
diseases associated with airway hyperreactivity. Their receptors are incorporated in membrane 
signaling platforms termed caveolae. These are Ω-shaped invaginations of the plasma 
membrane with a caveolar coat protein complex consisting of caveolins (Cav-1, -2 and -3) 
and cytoplasmic adapter proteins (cavin-1 to -4). There is evidence that Cav-3 might organize 
this caveolar coat complex in airway smooth muscle (ASM). To address this issue, we 
generated Cav-3-deficient mice to address the functional role of Cav-3 in ASM constriction 
using organ bath recording from extrapulmonary and videomicroscopy of precision cut-lung 
slices from intrapulmonary airways. Immunofluorescence, RT-PCR, real-time PCR, Western 
blotting and co-immunoprecipitation served to address the distribution and molecular 
composition of the caveolar coat complex in murine and human airways. Cav-3 was found in 
tracheal epithelium and ASM and was associated with Cav-1, cavin-1 and cavin-4. Cav-3 
deficiency neither had impact on protein expression of caveolar coat complex members nor on 
EHD-2 expression, a caveolae abundancy marker. Thus, specific aspects of caveolar function 
rather than caveolar abundancy are dependent on the expression of Cav-3. The response of 
extrapulmonary airway to muscarine was not altered in Cav-3
-/-
 mice, whereas a considerable 
increase in muscarinic bronchoconstriction was observed in Cav-3
-/-
 intrapulmonary bronchi. 
This demonstrates an inhibitory regulatory role of Cav-3 in cholinergic bronchoconstriction. 
Cav-3 was previously found to interact with the muscarinic receptor subtype 2 (M2R) in 
bronchial SM, and in cardiac myocytes it couples M2R stimulation with endothelial NO 
synthase (eNOS) activation. Thus, the depletion of Cav-3 might cause an increased 
muscarine-induced bronchoconstriction through disruption of M2R-Cav-3-eNOS. Cav-3 
deficiency fully abrogated serotonin-induced constriction of extrapulmonary airways while 
leaving intrapulmonary airways unaffected. Serotonergic airway constriction in murine 
extrapulmonary is considered to be indirectly mediated through ACh release from epithelial 
cells or nerve fibers. Since muscarinic constriction of extrapulmonary airways was unaffected 
in Cav-3-/- mice, the cholinergic component of this indirect effect shall not be responsible for 
the abrogated serotonergic effect. The selective expression of Cav-3 in epithelial cells – 
present in tracheal but not in intrapulmonary bronchial epithelial cells – might explain the 
differential effects of Cav-3 deficiency on serotonergic ASM constriction. Potentially, these 
data warrant consideration during pharmacological modulation of the cholinergic and 
serotonergic responses and provide an opportunity to modulate airway hyperreactivity. 
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6 Zusammenfassung 
Acetylcholin (ACh) und Serotonin sind Bronchokonstriktoren von hoher klinischer Relevanz 
bei Erkrankungen, die mit bronchialer Hyperreagibilität einhergehen. Ihre Rezeptoren sind in 
spezialisierten Membrandomänen, Caveolae, organisiert. Dies sind Ω-förmige 
Membraneinstülpungen mit einem Proteingerüst aus Caveolinen (Cav-1, -2 und -3) und 
zytoplasmatischen Adapterproteinen (cavin-1 bis -4). Es gibt Hinweise, dass Cav-3 diesen 
Proteinkomplex in der glatten Atemwegsmuskulatur (ASM) organisiert. In dieser Arbeit 
wurde ein Cav-3-defizienter Mausstamm generiert und die funktionelle Rolle von Cav-3 in 
der ASM Konstriktion in Organbaduntersuchungen extrapulmonaler und 
videomikroskopischen Untersuchungen intrapulmonaler Bronchi in lebenden Lungenschnitten 
ermittelt. Die Verteilung und molekulare Zusammensetzung des caveolären Proteinkomplexes 
wurde mittels Immunfluoreszenz, RT-PCR, real-time PCR, Western blotting und Ko-
Immunpräzipitation in Atemwegen der Maus und des Menschen untersucht. Cav-3 fand sich 
im Trachealepithel sowie ASM und war mit Cav-1, cavin-1 und cavin-4 assoziiert. Cav-3- 
Defizienz hatte weder auf die Expression anderer Proteinkomplexmitglieder, noch auf die von 
EHD-2, ein Strukturmarker von Caveolae, Einfluss. Cav-3 determiniert daher zwar 
spezifische Aspekte der Caveolenfunktion, nicht aber die strukturelle Ausbildung von 
Caveolae. Die Reaktion extrapulmonaler Atemwege auf Muskarin war unverändert in Cav-3
-/-
 
Mäusen, während die muskarinergen Konstriktion intrapulmonaler Bronchi zunahm. Dies 
zeigt eine inhibitorische Regulation der cholinergen Bronchokonstriktion durch Cav-3. Für 
Cav-3 wurde bereits eine Interaktion mit dem muskarinischen Rezeptorsubtyp 2 (M2R) in 
bronchialen Glattmuskelzellen gezeigt, und es koppelt den M2R mit Aktivierung der 
endothelialen NO-Synthase (eNOS) in Kardiomyozyten. Der Verlust von Cav-3 könnte daher 
die muskarinerge Bronchokonstriktion durch Aufhebung der M2R-Cav-3-eNOS-Koppelung 
verstärken. Die serotonininduzierte Konstriktion extrapulmonaler Atemwege war bei Cav-3-
Defizienz völlig aufgehoben, während die der intrapulmonalen Bronchi unverändert blieb. Bei 
der serotonergen Kontraktion der extrapulmonalen Atemwege der Maus wird von einer 
indirekten Wirkung auf das Epithel oder Nervenfasern mit folgender ACh-Freisetzung 
ausgegangen. Da die cholinerge Konstriktion der extrapulmonalen Atemwege in Cav-3-/-- 
Mäusen unverändert war, ist diese Komponente der indirekten Wirkung nicht für den Verlust 
der serotonergen Kontraktion verantwortlich. Die selektive Expression von Cav-3 in 
trachealen, aber nicht bronchialen Epithelzellen, könnte den differenziellen Effekt der Cav-3-
Defizienz auf die serotonerge ASM Konstriktion der verschiedenen Abschnitte erklären. 
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Diese Daten sind bei der pharmakologischen Modulation der cholinergen und serotonergen 
Effekte zu berücksichtigen und könnten eine zusätzliche Möglichkeit zur Beeinflussung der 
Atemwegshyperreagibilität bieten. 
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